Drug, bio-affecting and body treating compositions inventions 03/08

20080075671 - Intranasally administering curcumin to the brain to treat alzheimer's disease: The present invention relates to intranasally administering a pharmaceutical composition comprising curcumin to an upper third of a nasal cavity of the mammal, wherein the curcumin is absorbed through a nasal mucosa and transported to the brain of the mammal.... Agent: Philip S. Johnson Johnson & Johnson

20080075674 - Cough suppressor: A cough suppressor according to the present invention includes a chewable inner layer having a predetermined flavor. Preferably, the inner layer is chewing gum. The cough suppressor also includes an active layer situated outside the inner layer and that includes a cough suppressant. In addition, a buffer layer completely separates... Agent: Harshaw Research, Inc.

20080075677 - Antioxidant complex and a cosmetic and pharmaceutical composition comprising said complex: The present invention relates to an antioxidant complex comprising from 0.000001% to 40.00000% by weight of at lest one cinnamiA acid, from 0.000001% to 40.00000% by weight of at least one carotenoid, from 0.000001% to 99.999998% by weight of vitamin E, and a cosmetically and pharmaceutically acceptable a carrier, all... Agent: Alston & Bird LLP

20080075679 - Compositions containing dark glitter: The invention relates to compositions containing glitter containing dark colorant as well as to methods of applying such compositions to keratin materials and kits containing such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080075725 - Novel immunointeractive molecules and uses thereof: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferentially immunointeractive with T cells in subjects having an allergy to the... Agent: Scully Scott Murphy & Presser, PC

20080075727 - Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a... Agent: Novartis Vaccines And Diagnostics Inc

20080075728 - Combination therapies of hmgb and complement inhibitors against inflammation: Compositions and methods are disclosed for treating a condition characterized by activation of an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box and an inhibitor of complement biological activity, and/or an antibody that binds an HMGB polypeptide or biologically active fragment thereof and an inhibitor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080075729 - Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders: The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting... Agent: Fish & Richardson P.C.

20080075786 - Antimicrobial agents derived from cream: Methods for interfering with the growth of fungi by exposing the fungi to an antimicrobial agent derived from cream, and more particularly, to methods for treating human fungal pathogens such as Candida albicans and Aspergillus fumigatus, through exposing the fungi to free fatty acids with antimicrobial activity derived from cream.... Agent: Gordon & Rees LLP

20080075787 - Therapeutic agent for ophthalmic diseases: A therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. Laennec, the active ingredient, exhibits a therapeutic effect on a wide variety of ophthalmic diseases by increasing tears and the like and is highly safe even though it is an animal-derived component. Therefore, the therapeutic agent... Agent: Birch Stewart Kolasch & Birch

20080075788 - Diammonium phosphate and other ammonium salts and their use in preventing clotting: The present invention relates to products, methods, and processes of various ammonium salts and their use as anti-coagulants.... Agent: Kilpatrick Stockton LLP - 55461

20080075789 - Genes differentially expressed in bipolar disorder and/or schizophrenia: This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or bipolar disorder thereby providing prognostic and diagnostic markers for the disorder. In addition genes are identified whose dysregulation provides markers that allow diagnostic distinction... Agent: Beyer Weaver LLP

20080069773 - Novel sodium channel: Novel sodium channel nucleic acids and polypeptides are disclosed herein. Methods of using the novel nucleic acids and polypeptides are also disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20080069777 - Conformation specific antibodies: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between... Agent: Gosz And Partners LLP

20080069776 - Histofluorescent stain for endoscopy: e

20080069781 - Treatment of periodontal disease with photosensitizers: A method and composition is disclosed for treating oral diseases, including inflammatory periodontal disease, by utilizing photosensitizing compounds in long term effect or timed release formulations, including local highly concentrated formulations in biofilms on teeth and implants and oral wounds as well as periodontal pockets, and activating the photosensitizers with... Agent: Bolesh J. Skutnik Phd, Jd

20080069782 - Method of inhibiting bacterial growth and biofilm formation with natural quorum sensing peptides: Methods for selectively manipulating a growth rate of a selected bacterium comprising the step of contacting the selected bacterium with a predetermined amount of a quorum sensing molecule to affect a change in the growth rate of the selected bacterium, wherein the quorum sensing molecule is species specific, and the... Agent: Hogan & Hartson L.L.P.

20080069783 - Oral cavity cleaning composition: The present invention provides an oral cavity cleaning composition, comprising 35˜50 parts by weight of tea leaves extract, 10˜25 parts by weight of Stevia leaf extract, 10˜25 parts by weight of lemon extract, 10˜15 parts by weight of mint leaf extract, 10˜20 parts by weight of Lonicerae Flos extract, 20˜30... Agent: Birch Stewart Kolasch & Birch

20080069788 - Basic aluminium halogenide complexes: Basic aluminum halide complexes obtained by reaction of aluminum metal with hydrohalic acid and an organic acid, where either the aluminum metal is dissolved in a mixture of hydrohalic acid and organic acid, or the aluminum metal is firstly dissolved in the hydrohalic acid and then the organic acid is... Agent: Clariant Corporation Intellectual Property Department

20080069791 - Means for stimulation and activation of hair growth by il-15: The present invention relates to the use of IL-15 polynucleotides, polypeptides or compounds which bind to an antibody which specifically recognizes the IL-15 polypeptide or which specifically bind to an IL-15 receptor alpha chain for the preparation of a composition for stimulating hair growth or for treating, preventing and/or ameliorating... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069806 - Method of screening for substances useful for transdifferentiation of microglia into neurons: According to the present invention, there is provided a method of screening for a substance useful for transdifferentiation of microglia into neurons, a method of producing neurons, and a method of treating a neurologic disorder.... Agent: Oliff & Berridge, PLC

20080069805 - Use of stem cells to cure genetic diseases in humans cure for sickle cell anemia: Transplant of donor perfectly matched HLA hematopoietic stem cell to cure Sickle cell anemia and other anemia such as leukemia. Sterilized In vivo transplantation of clinically adequate quantities of antibiotic protected HLA vector/or insertion corrected chimera stem cells, and switching protein. Stem cells can be transfected for Hbg SS, and... Agent: Bruce M. Williams

20080069808 - Ec sod and cell transducing ec sod and use thereof: The present invention relates to an EC SOD, a cell-transducing EC SOLD, and the use thereof. More particularly, the present invention relates to an EC SOD, an EC SOD fusion protein enhanced Cell-transduction ability, and the use thereof for preventing or treating skin diseases.... Agent: Buchanan, Ingersoll & Rooney PC

20080069770 - Nucleotide sequence coding for variable regions of beta chains of human t lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses: The present invention relates to new nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080069771 - Oxygenated polymerized hemoglobin solutions and their uses for tissue visualization: An oxygenated Hemoglobin (Hb) solution includes from about 10 g to about 250 g of polymerized Hb per liter of solution. About 80% by weight, or greater, of the polymerized Hb of the oxygenated hemoglobin solution is oxyhemoglobin. About 18% by weight, or less, of the polymerized Hb has a... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080069772 - Treatment of transformed or infected biological cells: The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method... Agent: Marshall, Gerstein & Borun LLP

20080069774 - Proteomic antisense molecular shield and targeting: The present invention provides compositions and methods for shielding and directing agents to biological targets in cellular systems for therapeutic, prophylactic, and diagnostic uses. Vascular devices are also provided which have coated surfaces that contain proteomic antisense, as well as therapeutic and other biological agents attached thereto.... Agent: Millen, White, Zelano & Branigan, P.C.

20080069778 - Polymer-encapsulated microspheres: A polymer-encapsulated phospholipid microsphere, comprising a plurality of lipid molecules disposed in a liquid and arranged to define an enclosed space, and one or more polymers partially or completely encapsulating that enclosed space. The one or more polymers may be functionalized with either a therapeutic agent and/or a targeting ligand... Agent: Dale F. Regelman

20080069775 - Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.... Agent: Faegre & Benson LLP Patent Docketing

20080069779 - Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof: Vitamin and flavonoid containing compositions are provided that are stable to degradation. Stabilized compositions include one or more features including a hygroscopic solvent at a sufficient concentration to provide an Aw value of the hygroscopic vitamin and or flavonoid containing composition of less than 0.9, antioxidant flavonoids that are preferentially... Agent: Wilmerhale/boston

20080069780 - High concentration single phase gycol aerosol air sanitizer with dimethyl ether propellant/solvent: Improved single-phase aerosol spray air sanitizers and deodorizers are disclosed. The preferred active ingredient for the air sanitization is a high concentration of triethylene glycol (TEG), in a single-phase aerosol formulation made possible by the use of dimethyl ether (DME) as a propellant. The combination of TEG and DME enables... Agent: S.c. Johnson & Son, Inc.

20080069785 - Pest-control compositions, and methods and products utilizing same: Pest-combating compositions containing pest-control actives are formulated for sustained pest-combating efficacy, utilizing actives fatty acids, undecanone, and/or soy methyl ester in varying combinations. Pest-combating includes both repellency and killing of pests. In specific formulations, the pest-combating composition includes any one, two or three of the active agents soy methyl ester,... Agent: Intellectual Property / Technology Law

20080069784 - Regulation of mammalian keratinous tissue using skin and/or hair care actives: Personal care compositions containing an active selected from the group consisting of Lauryl p-Cresol Ketoxime, Bis-abolol and ginger extract, 4-(1-Phenylethyl)1,3-benzenediol, Lupin (Lupinus albus) oil & wheat (Triticum vulgare) germ oil unsaponifiables, Hydrolyzed lupin protein, Extract of L-lysine and L-arginine peptides, Oil soluble vitamin C, Evodia rutaecarpa fruit extract, Zinc pidolate... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080069786 - Polycondensate, composition, treatment process, and preparation process: Polycondensate, composition containing it, especially a nail varnish composition, and process for preparation. The polycondensate may be obtained by reacting: a polyol comprising 3 to 6 hydroxyl groups; a saturated or unsaturated non-aromatic monocarboxylic acid; an aromatic monocarboxylic acid containing 7 to 11 carbon atoms; and a saturated or unsaturated,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069787 - Acidic composition for external use, and agent for accelerating penetration into skin or the like of cosmetic preparation, hair-growing agent and preparation for external use each containing the composition: An acidic composition for external use which contains an acidic poly saccharide and water as essential ingredients, and an agent for accelerating the penetration into skin or the like of a cosmetic preparation, hair-growing agent or preparation for external use, each containing the composition. The composition is easy to manufacture,... Agent: Watchstone P+d, PLC

20080069789 - N-alkylheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine: The present disclosure is directed to a family of N-alkylheteroaryl secondary para-phenylenediamines, to their preparation, and to a cosmetic composition for dyeing keratin fibers, for example, human keratin fibers such as the hair, comprising, in a suitable dyeing medium, at least one N-alkylheteroaryl secondary para-phenylenediamine. Further disclosed herein is a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080069790 - Pre-shave preparation with enhanced lubricity using carboxy silicone polymer: Pre-shave compositions to lubricate skin during electric shaving that comprise at least one carboxy silicone polymer and a volatile component to serve as a carrier to the polymer. The pre-shave composition lubricates the skin to reduce skin friction between the electric razor and the skin surface, provides a closer shave,... Agent: St. Onge Steward Johnston & Reens, LLC

20080069792 - Polyamino acid derivatives and use thereof in compositions for treating keratin fibers: The invention concerns the use in a cosmetic composition of at least a poly-aminoacid of general formula (1) in which X is —O—, —S— or —NR3; R1 represents in particular a hydrogen atom or a C1-C40 alkyl radical; R2 represents in particular a hydrogen atom or an optionally substituted alkyl... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080069793 - Surfactant-free cosmetic, dermatological and pharmaceutical agents: The invention provides surfactant-free cosmetic, pharmaceutical, and dermatological compositions comprising at least one copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) if desired, one or more further olefinically unsaturated, noncationic comonomers, C) if desired, one or more olefinically unsaturated, cationic comonomers, D) if desired, one or more... Agent: Clariant Corporation Intellectual Property Department

20080069794 - Procyanidin-l-arginine combinations: The invention relates to compositions having an enhanced level of cocoa polyphenol and L-arginine which are effective in inducing vasodilation. The invention also relates to products including foods such as confectionary and pet foods, comprising cocoa polyphenols and L-arginine which are useful for inducing vasodilation.... Agent: Nada Jain, P.C.

20080069795 - Amelioration of drug-induced toxicity: Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the toxicity, permitting the use of cisplatin at levels and for durations which treat cancers more effectively. Modulation and depletion can be... Agent: Banner & Witcoff, Ltd.

20080069796 - Low dose treatment with an interleukin-11 analog: The invention relates to an analog of human interleukin-11 (IL-11) polypeptide which has increased potency and stability relative to wild-type IL-11 and which is therapeutically effective at low doses.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069797 - Rapamycin and il-10 for the treatment of immune diseases: The invention discloses a combined preparation containing IL-10 and rapamycin, able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune responses mediated by T cells.... Agent: Young & Thompson

20080069798 - Use of il-22 for the treatment of conditions of metabolic disorders: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.... Agent: EagleIPLimited

20080069799 - Use of il-22 for the treatment of conditions of metabolic disorders: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.... Agent: EagleIPLimited

20080069800 - System for high production of natural and personalized interferons: The present invention generally relates to systems and methods for the production of high amounts of personalized interferons (IFNs), which are IFNs produced from the cells of the patient to whom the IFN is to be administered, for therapeutic and research uses. The system can also be used to produce... Agent: Sheridan Ross PC

20080069801 - Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications: Biopolymer beads and hydrogels are useful in the remodeling, repair and reconstruction of the heart, as well as in modification of electrical conduction in the heart. Various types of beads are useful, including beads comprising a core of alginate polymers which may or may not be bonded to peptides; beads... Agent: Cyr & Associates, P.A.

20080069803 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions vectors: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle... Agent: Robins & Pasternak

20080069802 - Modified virus: Modified viral particles wherein the viral particles, typically adenoviral particles, are modified by glycosylation and the use of the modified viral particles to deliver heterologous nucleic acid to cells. Also disclosed are pharmaceutical compositions comprising the same and method of treatment using the same.... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20080069804 - Alphavirus replicon packaging constructs: Provided herein are modified, functional 5′ amplification sequences that are defective packaging signals. Also provided are compositions and methods comprising these modified 5′ amplification sequences.... Agent: Novartis Vaccines And Diagnostics Inc.

20080069807 - Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders: Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused... Agent: Venable LLP

20080069809 - Compositions and methods for the diagnosis and treatment of cancer: The present invention relates generally to the fields of diagnosis and treatment of cancer. More particularly, the present invention provides a method of determining the likely or relative sensitivity of cancer cells to a particular anti-cancer agent prior to or during anti-cancer treatment. Therapeutic protocols for the treatment of cancer... Agent: The Mccallum Law Firm, P. C.

20080069810 - Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and TAFI or a TAFI-related polypeptide, and the use thereof for treating bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department

20080069811 - Fsh and fsh receptor modulator compositions and methods for inhibiting osteclastic bone resorption and bone loss in osteoporosis: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.... Agent: Crowell & Moring Intellectual Property Group

20080069812 - Iap bir domain binding compounds: e

20080069813 - Isolated bovine igg heavy chain protein and its use as an antimicrobial: A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080069815 - Anti-osteopontin antibody and use thereof: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069817 - Heteroaryl-fused pyrimidinyl compounds as anticancer agents: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with... Agent: Chiron Corporation Intellectual Property - R440

20080069816 - Humanized anti-cea t84.66 antibody and uses thereof: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to... Agent: Perkins Coie LLP

20080069814 - Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof: The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069819 - Method and composition for detecting cancer by means of detection of epstein-barr virus nuclear antigen 2 coactivator p100: The present invention relates to a method for diagnosing cancer and a detection reagent based on detection of Epstein-Barr virus nuclear antigen 2 (EBNA2) coactivator p100 contained in a specimen, and a method for treating cancer by controlling expression of EBNA2 coactivator p100 protein or a gene thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069818 - Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents: The present invention provides compositions and methods for increasing the amount of active Syk protein kinase in a cell. The compositions and methods are useful for increasing the efficacy of anti-neoplastic agents, such as those used to treat leukemia, and thus for treatment of cancers, including leukemias. They are also... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20080069820 - Multispecific antibodies: The invention provides multispecific antibodies and methods of making and using such antibodies.... Agent: Clark & Elbing LLP

20080069821 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... Agent: Johnathan Klein-evans

20080069822 - Anti-orthopoxvirus recombinant polyclonal antibody: Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069823 - Attenuation of reperfusion injury: Compositions for and methods of attenuating and/or preventing ischemia-reperfusion injury (IRI) are provided. One method comprises administering to a patient in need thereof an agent that binds phosphatidylserine (PS) located on cell surfaces, i.e., PS binding agent. Another method comprises administering to an organ transplant recipient a therapeutic composition comprising... Agent: Swanson & Bratschun, L.L.C.

20080069824 - Size-variable strain-specific protective antigen for potomac horse fever: An isolated and purified antigen which is expressed by a wild-type E. risticii strain and is specific to the stain. The present invention also relates to nucleic acid constructs which encode the antigen, expression vectors, transformed host cells, and methods for producing the antigen.... Agent: Intervet Inc. Patent Department

20080069828 - Methods, kits, and antibodies for detecting parathyroid hormone: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or... Agent: Morrison & Foerster LLP

20080069827 - Mirna of hsv-lat and uses thereof: This invention relates to treatment of Herpes Symplex Virus infection. Specifically, the invention relates to the use of a newly discovered miRNA in the silencing of HSV-LAT gene, which is responsible for the prevention of apoptosis of infected neuronal cells and the maintenance of latency.... Agent: Pearl Cohen Zedek Latzer, LLP

20080069825 - Multiple cpg oligodeoxynucleotides and their use to induce an immune response: Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.... Agent: Klarquist Sparkman, LLP

20080069826 - Novel genes associated with the maintenance of differentiation of smooth muscle cells: A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No.... Agent: Fish & Richardson PC

20080069829 - Antigenic protein originating in malassezia: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the... Agent: Birch Stewart Kolasch & Birch

20080069830 - Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars: The invention comprises novel DNA, protein, and peptide sequences and novel vaccines, therapeutics and antibodies created with the novel DNA and peptides to prevent or treat SARS by administration of recombinant proteins, synthetic peptides, recombinant viruses, recombinant bacteria, DNA plasmids, RNA plasmids, or other molecular constructs or delivery systems.... Agent: David S. Dolberg

20080069831 - Yeast-based therapeutic for chronic hepatitis c infection: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with... Agent: Sheridan Ross PC

20080069832 - Vaccines: The present invention provides a vaccine composition comprising the B subunit of Shiga toxin or an immunologically functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen, and further comprising an adjuvant, provided that when the adjuvant is solely a metal salt it is formulated... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080069833 - Yeast-based vaccines as immunotherapy: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle... Agent: Sheridan Ross PC

20080069834 - Use of antioxidants for gene modulation: The invention provides (1) methods for modulating gene expression in senescent mammals by administering antioxidant-comprising compositions to the mammals and (2) antioxidant-comprising compositions that modulate gene expression and/or reduce the oxidative stress of such mammals.... Agent: Colgate-palmolive Company

20080069835 - Vaccine composition: The present invention relates to new, advantageous DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided.... Agent: Glaxosmithkline Corporate International Property - Uw2220

20080069837 - Composition and method for treating cancer using herpes virus: The present invention provides a herpes virus in which a non-essential gene for replication is inactivated. More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20080069836 - Method of using adenoviral vectors with increased immunogenicity in vivo: The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal an adenoviral vector comprising (a) a subgroup C fiber protein wherein a native coxsackievirus and adenovirus receptor (CAR)-binding site is disrupted, (b) a subgroup C penton base protein wherein a... Agent: Leydig Voit & Mayer, Ltd

20080069838 - Novel human virus causing severe acute respiratory syndrome (sars) and uses thereof: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention... Agent: Dickstein Shapiro LLP

20080069839 - Isolation and characterization of the precursor virus of human sars virus: sars-associated corona virus-like virus: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080069840 - Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines: An immunotherapeutic strategy is disclosed that combines antigen-encoding DNA vaccine compositions combined with siRNA directed to pro-apoptotic genes, primarily Bak and Bax, the products of which are known to lead to apoptotic death. Gene gun delivery (particle bombardment) of siRNA specific for Bak and/or Bax to antigen-expressing DCs prolongs the... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080069841 - Pharmaceutical compositions containing botulinum neurotoxin a2: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics select from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a... Agent: Jacobson Holman PLLC

20080069842 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20080069843 - Salmonella vaccine: The present invention relates to Salmonella bacteria. The invention also relates to methods of using Salmonella bacteria, including in vaccines based thereon that are useful for the prevention of microbial pathogenesis. Further, the invention relates to the use of such bacteria or the manufacture of such vaccines. The invention also... Agent: Trask Britt

20080069844 - Mucosal vaccine adjuvants containing bacterial flagellins as an active component: The present invention relates to mucosal vaccine adjuvants containing flagellins, the structural component of flagella, originated from Vibrio vulnificus, Salmonella typhimurium, and Listeria monocytogenes as an active component.... Agent: Sughrue Mion, PLLC

20080069846 - Protease, a gene therefor and the use thereof: The present invention relates to a protease, and more specifically to a protease derived from Aranicola proteolyticus, a gene coding for said enzyme, a gene expression system for said protease, a process for purifying the protease, and the uses of said protease in industrial applications, such as for example, detergents,... Agent: Sheridan Ross PC

20080069845 - Skin covering sheet for cosmetic preparation impregnation and process for producing the same , and face mask using sheet: A skin application sheet for being impregnated with a cosmetic preparation is provided which is suitable for a face mask and so on, and causes less irritation to skin, and has good application properties. A splittable conjugate fiber web containing at least 50% by mass of splittable conjugate fibers is... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080069847 - Materials containing negative ions and infrared materials for promoting health: Materials and fabrics compounded with negative ions and infrared materials to promote circulation of blood, ease stress and relieve body pain.... Agent: Weiss & Weiss

20080069848 - Device, method, and use for treatment of neuropathy involving nitric oxide: A device is provided that allows for target treatment of neuropathy, such as diabetic peripheral neuropathy, or neuropathy and ulcers resulting from said neuropathy. The device comprises a nitric oxide (NO) eluting polymer arranged to contact a treatment area, such that a therapeutic dose of nitric oxide is eluted from... Agent: Knobbe Martens Olson & Bear LLP

20080069849 - Novel antimicrobial peptides: The invention relates to the use of peptides, wherein at least one amino acid residue has been substituted to improve the efficacy of the antimicrobial peptide for the manufacturing of an antimicrobial composition. The composition can be used as a pharmaceutical composition to combat microorganisms, such as bacteria, virus, fungus,... Agent: Merchant & Gould PC

20080069850 - Multicomponent bioactive intravaginal ring: Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent diseases caused by infectious bacteria, fungi, virus, and retroviruses, without compromising the primary function of normally occurring, useful vaginal microflora in female patients.... Agent: Leigh P. Gregory

20080069851 - Substituted n-aminomethylene sulfonamides, production and use thereof as medicaments: Disclosed are compounds of the general formula (I), with the definitions of the substituents R1 to R5, A and X being detailed in the text, and to their physiologically tolerated salts, to processes for preparing these compounds and to the use thereof as inhibitors of hormone-sensitive lipase (HSL).... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080069853 - Antibody production method: A method of inducing the sustained release of antibodies in milk comprising the step of: a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20080069854 - Medical devices and methods of making and using: Disclosed herein are medical devices. The medical devices generally include a biocompatible nanostructured ceramic material having an average grain size dimension of about 1 nanometer to about 1000 nanometers, a strain to failure of at least about 1 percent, and a cross-sectional hardness greater than or equal to about 350... Agent: Cantor Colburn, LLP

20080069855 - Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss: The present invention provides a method for inhibiting the formation of scar tissue and/or exogenous bone at a wound site in a body of a patient. The method includes administering an amount of a biologic agent to the wound site, wherein the biologic agent is synovial fluid or cerebrospinal fluid.... Agent: Paul D. Bianco: Fleit, Kain, Gibbons, Gutman, Bongini, & Bianco P.l.

20080069852 - Porous osteoimplant: The invention is directed toward porous composites for application to a bone defect site to promote new bone growth. The inventive porous composites comprise a biocompatible polymer and a plurality of particles of bone-derived material, inorganic material, bone substitute material or composite material. In certain embodiments, the porous composites are... Agent: Choate, Hall & Stewart LLP

20080069856 - Compression molding method for making biomaterial composites: A process for making an implantable material comprising a composite of a biocompatible polymer and a bioactive agent. The composite combines desirable mechanical properties of polymers and the bioactivity of tissue or one or more component of tissue. More particularly, but not exclusively, the invention relates to methods for the... Agent: Krieg Devault LLP

20080069858 - Medical devices having biodegradable polymeric regions with overlying hard, thin layers: Implantable or insertable medical devices comprising a biodegradable polymeric region and a hard, thin layer disposed over the biodegradable polymeric region are described. Also described are methods for creating the same.... Agent: Mayer & Williams PC

20080069857 - Compositions and methods for inhibiting adhesions: The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellulose, or dextran, to a subject at a site where adhesions may form, e.g., as a consequence of surgery, injury, or infection. The... Agent: Choate, Hall & Stewart LLP

20080069859 - Method for treating neovascularization and intravitreal implants: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Birch Stewart Kolasch & Birch

20080069860 - Hyperphosphatemia in domestic animals: compositions and methods of treatment: The present invention is generally related to the treatment of hyperphosphatemia in domestic animals. It is specifically directed to compositions containing phosphate binders that are palatable to domestic animals and methods using such compositions. In a composition aspect, the present invention provides a composition that includes: a rare earth compound... Agent: Sheppard, Mullin, Richter & Hampton LLP

20080069861 - Probiotic/non-probiotic combinations: This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH,... Agent: National Starch And Chemical Company

20080069862 - Joint preserving nutritional vitamin, mineral and herbal pet supplement: A pet supplement includes a joint preserving and joint rebuilding composition comprising chicken collagen type II, glucosamine hydrochloride and chondroitin sulfate, a vitamin composition comprising vitamins C, D and K, a mineral composition comprising calcium, magnesium, zinc, copper, manganese and boron, a herbal anti-oxidant cofactor blend comprising citrus bioflavonoids, red... Agent: Ernest D. Buff Ernest D. Buff And Associates, LLC.

20080069863 - Device for treatment of disorders in the oral cavity with nitric oxide, and manufacturing process for the same: A device and method for therapeutical treatment of disorders in the oral cavity and a process for manufacturing of said device is disclosed. The device comprises a nitric oxide (NO) eluting polymer. The nitric oxide (NO) eluting polymer is configured to elute a therapeutic dosage of nitric oxide (NO) when... Agent: Knobbe Martens Olson & Bear LLP

20080069864 - Delivery system for cosmetic and skincare products: Cosmetic and skin care products are dispersed or encapsulated within a polymer matrix to provide a convenient means of storing and transporting the cosmetic or skin care product prior to use. Prior to use the polymer matrix is solubilized or melted to release the cosmetic or skin care product to... Agent: Perman & Green

20080069865 - Controlled release cgrp delivery composition for cardiovascular and renal indications: The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The... Agent: Morrison & Foerster LLP

20080069866 - Immunotherapeutic methods and compositions: This invention relates to methods and compositions introducing chemical entities into antigen presenting cells. The resulting presentation of said antigens on the surface of the antigen presenting cells gives an effect on the immune system. The invention also relates to the resulting modified antigen presenting cells and pharmaceutical compositions containing... Agent: Ked & Associates, LLP

20080069867 - Diagnostic and/or remedy for ovarian cancer: It was found that an antibody containing the amino acid sequences described in the sequence listing as SEQ ID NOS: 1 to 6 was an antibody having reactivity also to ovarian cancer, as well as the cancer species known so far such as gastric cancer, colon cancer and breast cancer,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069869 - Formulations and methods for modulating satiety: Formulations and methods of suppressing appetite and eliciting satiety in mammals are described. In some embodiments, oral administration of an effective amount of an appetite-suppressing peptide, in a composition that increases the bioavailability of the appetite-suppressing peptide, are effective to produce a feeling of satiety.... Agent: Mcdermott Will & Emery LLP

20080069868 - Irinotecan preparation: Provided is an irinotecan formulation capable of supporting irinotecan and/or a salt thereof in a closed vesicle carrier at a high concentration and existing in blood for a long period of time by dramatically improved retentivity in blood compared to a conventionally known irinotecan liposome formulation. That is, an irinotecan... Agent: Buchanan, Ingersoll & Rooney PC

20080069870 - Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection: The invention relates to a controlled release composition comprising a cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The controlled release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first... Agent: Synnestvedt & Lechner LLP

20080069871 - Hydrophobic abuse deterrent delivery system: Disclosed herein are oral dosage forms of therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20080069872 - Multi-layered controlled-release methylphenidate pellet: The present invention relates to a type of controlled-release multilayered methylphenidate pellet that does not need to be combined with another type of pellet. It allows the maintenance of therapeutic levels in the plasma during 12 hours with a single daily dose, avoiding repeated administrations throughout the day. The controlled-release... Agent: Sughrue Mion, PLLC

20080069873 - Controlled release system and method for manufacturing the same: The invention is directed to a pharmaceutical controlled release system for administration, particularly oral administration, of active substances with pH-dependent solubilities, comprising a) a core material containing or consisting of one or more pharmaceutically acceptable pH modifiers; b) optionally an insulating layer, c) a first layer containing or consisting of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080069874 - Kits for prevention and treatment of rhinitis: Kits providing a combination of one or more pharmaceutical information comprising one or more agent(s) for the treatment or alleviation of symptoms commonly associated with a cold and an immunonutritional composition comprising immunonutritional agent and methods of using these kits are described . The kits provide both the pharmaceutical agent(s)... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080069876 - Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use: Solid compositions capable of forming a paste, cream or gel suitable for use as a personal hygiene product when diluted with a liquid are disclosed. Methods of making and using solid compositions capable of forming a paste, cream or gel suitable for use as a personal hygiene product when diluted... Agent: Withers & Keys, LLC

20080069875 - Disintegrating buccal tablets: Disintegrating buccal tablets comprising a physiologically active material and a polyvinyl alcohol/polyethylene glycol graft copolymer are disclosed along with methods of making the same.... Agent: Connolly Bove Lodge & Hutz, LLP

20080069877 - Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance: The present invention relates to a nutriceutical and/or pharmaceutical composition for oral use containing a calcium-containing compound. The composition is in the form of tablets that are designed so that they have an acceptable taste and mouthfeel, whereby the tablets are chewable or suckable, and at the same time the... Agent: Edwards Angell Palmer & Dodge LLP

20080069878 - Drug delivery systems comprising solid solutions of weakly basic drugs: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080069879 - Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof: The present invention relates to stable solid dosage form and a dry process for preparing amorphous cefditoren pivoxil solid dosage forms and coating the solid dosage form with one or more layers of aqueous dispersion of film forming agents.... Agent: Jayadeep R. Deshmukh Ranbaxy Inc.

20080069880 - Enrobed core: An enrobed a core, such as a tablet core, that has a coating made of one or more patterned films each having portions that are visually distinct (e.g., differently colored) from one another and having a transition line segment between these visually distinct portions. At least a portion of an... Agent: Philip S. Johnson Johnson & Johnson

20080069881 - Abuse-resistant controlled-release opioid dosage form: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as... Agent: Ip Group Of Dla Piper US LLP

20080069882 - Novel preparation and administration form comprising an acid-labile active compound: Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in... Agent: Nath & Associates PLLC

20080069884 - Amide derivatives of hyaluronic acid in osteoarthrosis: The present invention concerns amide derivatives of hyaluronic acid (HA) and biomaterials made of amide derivatives of hyaluronic acid (HA), particularly the hexadecylamide of HA, administered by the intraarticular route as a partial/total substitute for synovial fluid to treat joints affected by o steoarthrosis (OA) as well as cases of... Agent: Hedman & Costigan P.C.

20080069883 - Prostaglandin compositions and methods for the treatment of vasospasm: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.... Agent: Mirick, O'connell, Demallie & Lougee, LLP

20080069885 - Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release and a duration of action of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080069886 - Spironolactone nanoparticles, compositions and methods related thereto: This invention relates to nanoparticles comprising spironolactone. The nanoparticles have a mean diameter, measured by photon spectroscopy, in the range of from about 300 nm to about 900 nm.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080069887 - Method for nanoparticle surface modification: The present disclosure discloses a method for making surface-modified nanoparticles. The surface of a nanoparticle is modified with an aminorganosilane and an alkylating agent in a one-pot synthesis to provide alkylamine surface-modified nanoparticles.... Agent: 3m Innovative Properties Company

20080069888 - Modified release formulations of at least one form of tramadol: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069889 - Compressible resilient granules and formulations prepared therefrom: The present invention provides resilient self-adhering granules which comprise a polysaccharide present in an amount from about 10 wt % to about 90 wt % and a binder having a viscosity from about 5,000 mPa·s to about 250,000 mPa·s present in an amount from about 90 wt % to about... Agent: Richard R. Muccino

20080069890 - Method for treating patients with implants of islets which have been kept in long term, in vitro culture: The invention relates to the use of macrobeads which have been kept in in vitro storage for long term culture, i.e., for at least about 8 months. The macrobeads surprisingly exhibit continued efficacy in producing therapeutically useful materials. The fact that the macrobeads can be used after long term culture... Agent: Fulbright & Jaworski, LLP

20080069891 - Abuse resistant drug formulation: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol... Agent: Cephalon, Inc.

20080069892 - Powder formulations: The present invention relates to powder formulations which consist of at least one agrochemical active substance, at least one polyurethane and/or polyurethane urea, and, if appropriate, additives and which have a particle diameter of less than 125 μm, to processes for the preparation of these formulations and to their use... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069894 - Bioresorbable polymer matrices and methods of making and using the same: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the... Agent: Caroline Nash Nash & Titus, LLC

20080069893 - Compositions for repair of defects in osseous tissues, and methods of making the same: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.... Agent: Morgan Lewis & Bockius LLP

20080069895 - Umbilical cord biomaterial for medical use: The present invention provides a biomaterial comprising a mammalian umbilical cord membrane. The biomaterial can additionally comprise Wharton's jelly and/or one or more umbilical cord vessels. The biomaterial is preferably dry, and can be flat, tubular, or shaped to fit a particular body structure. The invention further provides laminates comprising... Agent: Jones Day

20080069896 - Antitumor composition: Antitumor agents with high antitumor effect have much side-effect, and its activity decreases when the toxicity decreases. Thus, satisfactory antitumor effects are not always obtained. Therefore, development of an antitumor agent having a high antitumor effect, with less side-effect and low toxicity is awaited. The present invention is to provide... Agent: King & Spalding

20080069897 - Method for promoting and maintaining respiratory tract health: A method for promoting and maintaining respiratory tract health by moisturizing and cleansing a nasal membrane is disclosed. The method includes the steps of applying a drug-free, preservative-free composition to an interior portion of a nasal cavity using a spray applicator. The spray applicator includes a microbiological filter to prevent... Agent: Snell & Wilmer L.L.P. (main)

20080069898 - Topical compositions comprising myrica gale oil: The use of Myrica gale oil in the manufacture of a composition for the treatment of the skin or other exposed surfaces of the body is disclosed. Compositons prepared in accordance with the invention are particularly useful as anti-acne and anti-dandruff products. Myrica gale oil may bai used with other... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080069900 - Combination chemotherapy compositions and methods: This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention flier relates to compounds, compositions, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention.... Agent: Sughrue Mion, PLLC

20080069902 - Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the... Agent: Nektar Therapeutics

20080069899 - Pharmaceutical compositions comprising beta-carboline derivatives and use thereof for the treatment of cancer: The invention relates to the use of at least one compound of general formula (1) for the production of a medicament for the treatment of cancer.... Agent: Young & Thompson

20080069901 - Therapeutic agent for metastatic cancer and cancer metastasis inhibitor: To provide a therapeutic agent for metastatic cancer and a cancer metastasis inhibitor which are highly safe and efficaciously treat metastatic cancer and inhibit cancer metastasis, and especially efficaciously treat and inhibit cancer metastasis to bone and liver. There are provided a therapeutic agent for metastatic cancer and a cancer... Agent: Sughrue Mion, PLLC

20080069903 - Electrical producing creams: New electrical producing creams are provided. In one embodiment, the electrical producing creams comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA. In another embodiment, the electrical producing... Agent: Hovey Williams LLP

20080069904 - Inhibition of angiogenesis through nitric oxide tachyphylaxis: A method is provided for treating cancer in a mammalian subject by inhibiting angiogenesis through the administration to the subject of a therapeutically effective amount of a nitrate-containing compound and a therapeutically effective amount of an inorganic selenium-containing compound. Kits and systems are also disclosed for practicing the subject methods.... Agent: David W. Collins - Intellectual Property Law

20080069905 - Device for application of medicaments, manufacturing method therefor, and method of treatment: A therapeutic treatment device is provided, which comprises a compound comprising a drug and a nitric oxide (NO) eluting polymer arranged to contact a treatment site in or on a body. The device is acting as a booster for drug eluting patches, e.g. pharmaceuticals, vitamins, nicotin, nitroglycerin, whereby with advantage... Agent: Knobbe Martens Olson & Bear LLP

20080069906 - Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor: A medicament to decrease the adverse events of Orlistat, an oral lipase inhibitor, arranged to be taken in combination with Orlistat, comprising: an admixture of carminative herbs and one or more chelating agents to absorb and mechanically agitate non-digested fats.... Agent: Donald N. Halgren

20080069907 - Compositions for cancer prevention, treatment, or amelioration comprising papaya extract: The components of a brew/extract of leaves or other parts of the papaya plant (Carica papaya) or fractionated components thereof are effective in the prevention or treatment of stomach cancer, lung cancer, pancreatic cancer, colon cancer or other solid cancers, or lymphoma, leukemia or other blood cancers, and are very... Agent: Sughrue Mion, PLLC

20080069908 - Compositions for safe and effective regression of dermal vessel tortuosity in psoriatic lesions: Topical compositions for Safe and Effective regression of Dermal Vessel Tortuosity in Psoriatic Lesions in the form of ointment, cream, oil, soap and shampoo contain non aqueous herbal extract of Wrightia Tinctoria, cocos nucifera, and suitable pharmaceutically/cosmetically accepted excipients for dermal use.... Agent: Bregen Technical Consultants L.L.C.

20080069909 - Menopause disorder synergistic phyto-nutraceutical composition: A Phytoceutical composition for the prevention and treatment of menopause disorders and symptoms is provided. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from... Agent: Jose Olalde Rangel

20080069910 - Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy: To provide a composition for prevention, amelioration, or treatment of diabetes mellitus and/or diabetic nephropathy, which is less likely to cause any disadvantages such as side effects, and highly safe. [1] A composition for prevention, amelioration, or treatment of diabetes mellitus and/or diabetic nephropathy, containing one or more dietary fiber... Agent: Birch Stewart Kolasch & Birch

20080069911 - Plant extracts for the treatment of rheumatoid arthritis: The present invention provides a pharmaceutical composition comprising a crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng (PA) for the treatment of rheumatoid arthritis. The present invention also provides a use of the crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng for the manufacture of medicaments for treating... Agent: Ladas & Parry

20080069912 - Use of an acmella oleracea extract for the botox-like effect thereof in an anti-wrinkle cosmetic composition: Spilanthol, in the form of an Acmella oleracea extract, inhibits contractions in subcutaneous muscles, notably those of the face, and can be used as an anti-wrinkle product. A cosmetic treatment procedure for wrinkles consists of locally or subcutaneously applying an effective quantity of a composition based on spilanthol pure or... Agent: Heslin Rothenberg Farley & Mesiti PC

20080069913 - Anti-snoring composition: An anti-snoring composition including at least one lubricating substance and at least one bioadhesive substance which causes the lubricating substance to adhere to the mucocilliary cells located at pharynx level.... Agent: Ip Group Of Dla Piper US LLP

20080063599 - Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils: The invention relates to compounds having general formulae I, II and III, which can be used to diagnose and monitor diseases associated with the deposit of amyloid proteins in the central nervous system. The invention also relates to the use of the inventive compounds in the diagnosis of the aforementioned... Agent: Kramer & Amado, P.C.

20080063604 - Method and composition for the site-selective gene delivery using viruses: Methods and compositions for the site-selective delivery of a gene to a site within the body of an animal where virus not encapsulated within the microbubbles is inactivated, for example by treatment with a virus-inactivating agent.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080063611 - Dentifrice compositions: Stain-removal, desensitizing, anti-tartar and anti-gingivitis dentifrice compositions. The dentifrices comprise a fluoride agent; an abrasive agent; a proteolytic agent; a foaming agent; a sweetening/flavoring agent; an emulsifying agent; either desensitizing, anti-tartar or anti-gingivitis agents or combinations thereof; and a delivery agent. The dentifrices are visually pleasing and impart a soothing... Agent: Crowell & Moring LLP Intellectual Property Group

20080063614 - Skin compositions containing hydrocortisone: Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body... Agent: Dara L. Onofrio, Esq. C/o Onofrio Law

20080063615 - Color changing skin sealant: Iodine is used in about 80 percent of surgeries in the US to remove some level of microbial load on the skin prior to making an incision. Skin sealants are applied over skin preps to seal the skin and hold any remaining bacteria in place. Iodine produces a characteristic orange-brown... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080063616 - Antiperspirant compositions and methods for making same: A consumer product comprising packaging including a product chamber and an outer jacket at least partially surrounding the product chamber; and an antiperspirant composition disposed within the product chamber, wherein the composition exhibits an average standard deviation of less than or equal to about 5 of penetration peak force measurements... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080063619 - Cosmetic compositions with ethylene brassylate: A cosmetic composition is provided which includes tapioca starch and ethylene brassylate in a cosmetically acceptable carrier. The composition provides a silky afterfeel to skin.... Agent: Unilever Intellectual Property Group

20080063617 - Cosmetics formulations: A cosmetic formulation containing an alkylated chitosan derivative, a polybasic carboxylic acid or an oxidized polysaccharide, and water, for moisturizing and/or softening skin is provided. The formulation is in the physical state of a viscous liquid or a gel, and when applied to skin, serves to moisturize and soften the... Agent: Schwegman, Lundberg & Woessner, P.A.

20080063623 - Avian cytokines, such as il-12, comprising a p40 and/or p35 subunit and vaccines: Embodiments of the present invention generally relate to novel avian cytokines, to DNA sequences encoding these novel cytokines and to their use in adjuvants for vaccine purposes.... Agent: Intervet Inc. Patent Department

20080063628 - Methods to promote cell differentiation: A method for promoting the differentiation of cells by contacting cells with a chromatin-remodeling agent to increase the expression of a transcriptional regulator.... Agent: Philip S. Johnson Johnson & Johnson

20080063627 - Tissue graft materials containing biocompatible agent and methods of making and using same: The invention provides implantable tissue graft materials composed of a collagenous tissue scaffold and a biocompatible agent bonded to the tissue scaffold via an activated photoreactive group. The invention further provides methods including steps of obtaining a tissue graft material comprising a collagenous tissue scaffold; contacting the collagenous tissue scaffold... Agent: Kagan Binder, PLLC

20080063598 - Humanized antibody: Novel humanized and chimeric antibodies, humanized antibody fragments, polypeptides sequences of such antibodies and derivatives thereof that specifically bind AF-20 are provided as well as methods for their manufacture. These humanized and chimeric antibodies, antibody fragments and polypeptide sequences are useful in the treatment of cancers that express AF-20, as... Agent: Goodwin Procter LLP

20080063600 - Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissued derived products: B-cells have been identified as being the crucial carriers of infectivity in the spread of transmissible spongiform encephalopathy within an infected organism. In a second step, B-cells may infect further components_of the immune system, e.g. T-cells. Accordingly, the present invention provides B-cell and T-cell specific ligands for the use in... Agent: Dykema Gossett PLLC

20080063601 - Compositions and methods relating to polycystic kidney disease: Described herein are therapeutic strategies (methods and compositions) useful for treating conditions in which cilia are affected and which manifest with cysts and/or fibrosis, such as conditions in which the kidney, pancreas, liver and/or spleen are affected and contain cysts. Particular embodiments described herein are therapeutic strategies in which PC-2... Agent: Wolf Greenfield & Sacks, P.C.

20080063602 - Magnetic resonance imaging contrast agents synthesized using ring-opening metathesis polymerization: Polymeric chelating agents and metal chelates, particularly those of lanthanide metals and more specifically those of Gd(III), useful as contrast agents in magnetic resonance imaging (MRI) for therapeutic and diagnostic applications as well as clinical and biomedical research applications. The polymeric chelates are generated using ring-opening metathesis polymerization (ROMP). Polymers... Agent: Greenlee Winner And Sullivan P C

20080063605 - Method of enhancing visualization of atherosclerotic plaque: The invention relates to a method and a corresponding device for multipurposely supporting a randomly shaped and/or possibly complex with respect to a rigid base (11) part (1) by fixing a working reference, wherein the inventive method consist in interposing at least one deformable constant-volume chamber (3) which is sealed... Agent: Wilson Sonsini Goodrich & Rosati

20080063603 - Ultrasound contrast agents and methods of making and using them: The invention is directed to injectable suspensions of gas-filled microvesicles, as well as methods of preparing and using the same, especially as ultrasound contrast agents.... Agent: Kramer Levin Naftalis & Frankel LLP

20080063606 - Pulmonary delivery of aminoglycoside: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.... Agent: Nektar Therapeutics

20080063607 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent... Agent: Wilmerhale/boston

20080063608 - Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid, and betamimetic: wherein X− is an anion with a single negative charge; (b) a corticosteroid; and (c) a betamimetic, wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof, processes for preparing them, and their use in the treatment of respiratory diseases.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080063609 - Compressed chewing gum tablet: The invention relates to a chewing gum tablet (20) comprising at least two cohered chewing gum modules (21, 22, 23), said tableted chewing gum being formed by compression of chewing gum granules, at least one of said chewing gum modules comprising gum base granules, said gum base granules comprising an... Agent: Cantor Colburn, LLP

20080063610 - Use of beta-homocyclocitral as an agent against bad breath: The use of beta-homocyclocitral is described as an agent (i) to inhibit and/or prevent the growth of and/or to destroy micro-organisms causing bad breath and/or (ii) to combat bad breath.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080063612 - Dental whitening compositions: A two-component whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be an unfoamed, a foamed or a foamable composition. The system has a first component with at least one peroxide compound, at least one source of phosphate and at least one gelling agent; and... Agent: Discus Dental Impressions, Inc.

20080063613 - Syndet bars having ultraviolet radiation protection: The present invention is drawn to a syndet soap bar that after the washing process leaves a residual deposit on a substrate that provides protection from ultraviolet radiation comprising (a) a non-emulsifying surfactant having an HLB greater than 15; (b) from greater than 10% to about 25% by weight red... Agent: Louis C. Paul Louis C. Paul & Associates

20080063618 - Personal care compositions comprising a zinc containing material in an aqueous surfactant composition: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080063620 - Novel reverse thermo-sensitive block copolymers: The invention provides a responsive polymeric system, comprising: a polymeric responsive component capable of undergoing a transition that results in a sharp increase in viscosity in response to a change in temperature at a predetermined body site; wherein the polymeric component comprises hydrophilic and hydrophobic segments covalently bound within the... Agent: Foley And Lardner LLP Suite 500

20080063621 - Surface cross-linked lipidic particles, methods of production and uses therefor: A method for producing a composition of lipidic particles coated with a cross-linked surface mesh, the method comprising the steps of: (i) preparing lipidic particles comprising pharmaceutically acceptable lipids, (ii) binding hydrophilic polymer chains to the surface of the lipidic particles, and (iii) cross-linking the hydrophilic polymer chains to form... Agent: David S. Resnick

20080063622 - Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and... Agent: Peacock Myers, P.C.

20080063624 - Methods to mobilize progenitor/stem cells: wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain,... Agent: Morrison & Foerster LLP

20080063625 - Method for managing cholesterol with a serum-free and mitogen-free cytokine mixture: Methods for treating or preventing a disease or disorder, for example, cardiovascular disease, dyslipidemia; dyslipoproteinemia; hyperlipidemia; a disorder of glucose metabolism; Syndrome X; a peroxisome proliferator activated receptor-associated disorder; obesity; hypertension; and renal disease with a serum-free and mitogen-free mixture comprised of specific ratios of cytokines IL-1β, TNF-α, IFN-γ and... Agent: Hahn & Voight PLLC

20080063626 - Minimization of drug oxidation in drug irradiated excipients formulations: This invention relates to compositions and methods for preventing oxidation of beneficial agents that comprise at least one beneficial agent and an excipient, wherein the excipient has been irradiated and annealed.... Agent: Woodcock Washburn LLP

20080063629 - Method for production of neutrophils and uses therefor: An in vitro method for the differentiation of functionally mature neutrophils from stem cells is disclosed. Also disclosed are methods of producing genetically modified neutrophils in vitro and methods of using the neutrophils produced according to the invention.... Agent: Sheridan Ross PC

20080063630 - Method for targeting a polypeptide onto cellular surface: The present invention relates to a polypeptide having an activity for targeting a heterogeneous polypeptide to a surface of cytoplasmic membrane, a nucleic acid encoding the polypeptide, a construct for introducing into a cell, comprising the nucleic acid, a transformant harboring a carrier for introducing into a cell, a method... Agent: Birch Stewart Kolasch & Birch

20080063631 - Apoptotic entities for use in treatment of endothelium dysfunction disorders: Treatment and/or prophylaxis of endothelial dysfunction-related disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells.... Agent: Foley & Lardner LLP

20080063632 - Recombinant host for producing l-asparaginase ii: The invention provides a recombinant Escherichia coli host cell for producing an Escherichia coli-asparaginase II enzyme. The host cell includes an Escherichia coli chromosome and at least one copy of a recombinant extrachromosomal vector, wherein the recombinant extrachromosomal vector encodes the L-asparaginase II enzyme, wherein the host cell chromosome also... Agent: Lucas & Mercanti, LLP

20080063633 - Obtaining and use of therapeutic antibodies entering into the cell: The invention relates to the development of a novel technology of (cancer-) specific antibodies entering into the cell and their use for treatment of human diseases (primarily cancer). Such antibody (drug) would act by directly modulating the cancer-generating signals. The expected effects and principles of action of such antibodies are... Agent: Birch Stewart Kolasch & Birch

20080063634 - Human antibodies that bind human il-12 and methods for producing: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody... Agent: Lahive & Cockfield, LLP

20080063638 - Mitotic kinesin-like protein-1, mklp1, and uses therof priority: The present invention discloses uses for the MKLP1 gene and/or polypeptide and/or modulators thereof in the diagnosis and treatment of apoptosis-related diseases.... Agent: John P. White Cooper & Dunham LLP

20080063637 - Regulation of oncogenesis by akt-specific isoforms: Expression of the polyoma middle T antigen (PyMT) or the HER2/Neu oncogene in the mammary gland of transgenic mice from MMTV LTR-driven expression constructs, gives rise to mammary adenocarcinomas. Here we show that ablation of Akt1 inhibits, while ablation of Akt2 accelerates tumor induction by both transgenes. The tumors arising... Agent: Medlen & Carroll, LLP

20080063635 - Stabilized human igg4 antibodies: A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4... Agent: Foley And Lardner LLP Suite 500

20080063636 - Variant amyloid protein: It is intended to provide a novel amyloid protein (human variant amyloid protein) useful as an antigen molecule or the like for improving a vaccine therapy. This human variant amyloid protein is a protein with deletion of Glu at 22nd, Ala at 21st, or Asp at 23rd in a normal... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080063639 - Method for the treatment of psoriasis comprising novel anti-igf-ir antibodies: The present invention relates to a method for the prevention or for the treatment of psoriasis comprising administering to a patient in need thereof an effective amount of an isolated antibody, or one of its functional fragments, capable of binding to the human insulin-like growth factor I receptor IGF-IR. The... Agent: Buchanan, Ingersoll & Rooney PC

20080063640 - Pin-prc transition genes: Objective methods for diagnosing a predisposition to developing prostate cancer (PRC) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of PRC-associated gene that discriminate between PRC and PIN. The present invention further provides methods of screening for therapeutic agents useful in the treatment... Agent: Townsend And Townsend And Crew, LLP

20080063642 - Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in... Agent: Jones Day

20080063641 - Monovalent antibody fragments useful as therapeutics: The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment.... Agent: Genentech, Inc.

20080063643 - Peptide derived from hepatitis c virus: Disclosed is a peptide derived from hepatitis C virus comprising an HLA-binding motif in its sequence and being recognized by an antibody detected in a patient with hepatitis C virus (HCV) infection. The peptide of the present invention is useful in diagnosing hepatitis C virus, treating hepatitis C, and predicting... Agent: Birch Stewart Kolasch & Birch

20080063644 - Il-18 receptor antagonist and pharmaceutical composition containing the antagonist: Provided is an IL-18 receptor antibody usable for immunohistochemistry, which functions as an IL-18 receptor antagonist. Also provided is a pharmaceutical composition and method for preventing and/or treating an IL-18-dependent disorder, particularly skin thickening caused by ultraviolet, using the antibody. An antibody against the IL-18 receptor α subunit, which is... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080063645 - Endotoxin-adsorbent for the prevention and treatment of autoimmune diseases: It is believed that the abnormal absorption of endotoxin present in the gastrointestinal tract relates to the pathogenesis of autoimmune diseases such as rheumatoid arthritis. In an animal model for rheumatoid arthritis, it is observed that arthritis is improved by removing endotoxin. The present invention provides endotoxin-adsorbent, which is capable... Agent: Flynn Thiel Boutell & Tanis, P.C.

20080063646 - Treatment of inflammatory bowel diseases with anti-ip-10 antibodies: The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080063647 - Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method... Agent: Knobbe Martens Olson & Bear LLP

20080063649 - Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.... Agent: Johnathan Klein-evans

20080063648 - Vaccination of young animals against lawsonia intracellularis infections: The present invention provides a method of vaccinating a young animal against L. intracellularis infection comprising the step of administering to said animal an effective dose of L. intracellularis antigen. It also provides a method of vaccinating an animal, preferably a young animal, having anti-L.intracellularis antibodies or is exposed to... Agent: Erickson & Kleypas, L.L.C. Boehringer Ingelheim

20080063650 - Mcrp antagonists and their uses: A therapeutic composition for treating a proliferative disorder includes a membrane-bound complement regulatory protein (mCRP) antagonist, a therapeutic ligand that is capable of activating complement and β-glucan. mCRPs are overexpressed in some tumor types and are shown to inhibit complement activation. mCRP antagonists inhibit or block mCRP activity such that... Agent: Biopolymer Engineering, Inc. Dba Biothera, Inc. C/o Intellevate

20080063651 - Fibronectin derivative fc fusions: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080063652 - Methods for production of regulatory t cells and uses thereof: The invention provides culture systems for the generation, expansion and isolation of regulatory T cells. These culture systems can be used to screen for factors that modulate regulatory T cell development. Regulatory T cells derived from such cultures can be used in various in vitro and in vivo applications, as... Agent: Wolf Greenfield & Sacks, P.C.

20080063653 - Human cytotoxic t-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of muc-1: Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.... Agent: Edwards Angell Palmer & Dodge LLP

20080063654 - Prostate cancer vaccine: Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical... Agent: Quarles & Brady LLP

20080063655 - Brachyspira hyodysenteriae vaccine: The present invention relates to nucleic acid sequences encoding a 30 kD Brachyspira hyodysenteriae lipoprotein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such lipoproteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or... Agent: Intervet Inc. Patent Department

20080063656 - Adenoviral vector compositions: Applicants disclose herein novel methods, vectors, and vector compositions for improving the efficiency of adenoviral vectors in the delivery and expression of heterologous nucleic acid encoding a polypeptide(s) (e.g, a protein or antigen) of interest. Adenoviral infection is quite common in the general population, and a large percentage of people... Agent: Merck And Co., Inc

20080063657 - Compositions comprising pathogen-associated molecular patterns and antigens and methods of use thereof: Compositions comprise at least a portion of an antigen and at least a portion of a flagellin that lacks a hinge region. Compositions, fusion proteins and polypeptides comprise at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one viral protein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080063658 - Synergistic hiv/aids and/or immune disease phyto-nutraceutical composition: Phytoceutical composition for the prevention and treatment of HIV/AIDS and/or immune disorders. A specific combination of extracts of plants is taught, as well as the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20080063660 - Method to reduce the physiologic effects of drugs on mammals: A method to reduce the physiologic effects of drugs in vivo by inducing specific anti-drug antibodies using drugs conjugated to carrier molecules so as to reduce a drug's toxicity and its physiologic effects upon the recipient. This method includes the treatment and prophylactic prevention of drug abuse, specifically for cocaine... Agent: Jones Day

20080063661 - Human papilloma virus treatment: Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating... Agent: Fish & Richardson PC

20080063662 - Vaccine: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080063663 - Hemorrhagic feline calicivirus: The present invention relates to a vaccine for immunization against a viral infection caused by a hemorrhagic feline calicivirus (hFCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats... Agent: Townsend And Townsend And Crew, LLP

20080063664 - High-yield transgenic mammalian expression system for generating virus-like particles: The present invention provides a method utilizing mammalian expression system for generating virus-like particles (VLPs) of mammalian-hosted viruses, particularly SARS-CoV. The method of the present invention involves expression of viral structural proteins in Vero cells and thereby obtaining recombinant VLPs in the culture medium. SARS-VLPs generated by the method of... Agent: Panitch Schwarze Belisario & Nadel LLP

20080063665 - Meningococcal outer membarne vesicles: OMVs targeted against specific epidemic strains can be highly effective in controlling localised outbreaks of disease. In combination with large-scale and reproducible manufacturing techniques, a vaccine can be rapidly produced after an outbreak. The invention provides a method for preparing a meningococcal outer membrane vesicle (OMV) vaccine, comprising the steps... Agent: Novartis Vaccines And Diagnostics Inc.

20080063666 - New lactic bacteria useful as probiotics: V

20080063667 - Proder p 1 expressed in a prokaryotic cell: This invention relates to novel methods for producing recombinant allergens, including but not limited to proDer p 1, the precursor form of the major protein allergen from Dermatophagoides pteronyssinus Der p 1, and to recombinant allergens produced by such methods. The invention further relates to the use of said recombinant... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080063668 - Nitroimidazole and terconazole composition and method: An aqueous tinidazole and terconazole composition comprises at least about 0.5 percent by weight of tinidazole and about 0.4 to about 3 percent by weight of terconazole dissolved in water, and a crystallization-inhibiting amount of an organic acid. Preferably the organic acid is citric acid. The composition is free from... Agent: Olson & Cepuritis, Ltd.

20080063670 - Nitroimidazole composition and method: An aqueous nitroimidazole composition comprises metronidazole, tinidazole or a combination thereof at a concentration greater than the solubility of the free base form of the nitroimidazole in water at 20° C., and a nitroimidazole crystallization-inhibiting amount of at least one organic acid. The organic acid preferably is a lower alkyl... Agent: Olson & Cepuritis, Ltd.

20080063669 - Terconazole composition and method: An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of an organic acid. Preferably the organic acid is a water soluble alkyl carboxylic acid, a polybasic organic acid, or a combination thereof. The composition is free from... Agent: Olson & Cepuritis, Ltd.

20080063671 - Hemostatic bone graft: The present invention provides a hemostatic bone graft product and method. Hemostatic bone grafts may include demineralized bone matrix in combination with additives. In one embodiment, the graft comprises demineralized bone and polyethylene glycol. Methods for producing the hemostatic bone graft may include mixing demineralized bone with additives to facilitate... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080063672 - Device for applying a cosmetic product: A device for applying a cosmetic product, such as a make-up product (blush or “fard”, face powder, corrector, base make-up, eye-shadow, etc.) is defined by a cap housing a solid mass of cosmetic product having a contact surface, and by a brush housed removably inside the cap and movable inside... Agent: Blank Rome LLP

20080063673 - Method and kit for treatment/prevention of hair loss: The method includes the steps of cleansing of the scalp sufficiently to remove material which would otherwise block antiviral medication from reaching hair follicles, heating the scalp to increase the absorption of the antiviral medication and applying the antiviral medication to the scalp in effective amount to suppress viral replication... Agent: Jensen + Puntigam, P.s.

20080063675 - Aloe powder, aloe juice, and method for producing the same: In the conventional technology, macromolecular polysaccharides, which the aloe vera gel inherently has, are broken down into small molecules for the following reasons: First, cellulose is broken down by the enzyme such as cellulose; Second, agitation in the cellulose breakdown process by the enzyme of cellulase and the like is... Agent: Hedman & Costigan P.C.

20080063674 - Cosmetic composition containing protein hydrolysates: The invention provides cosmetic compositions comprising a protein hydrolysate and a cosmetically acceptable excipient, wherein the protein hydrolysate has a high content of peptides with a terminal proline.... Agent: Nixon & Vanderhye, PC

20080063676 - Method for preparing a two-coloured cosmetic: The invention relates to a method for preparing a two-colour cosmetic product, particularly a two-colour cosmetic product intended for make-up, which consists of a base cosmetic product and a decorative cosmetic product in a different colour being applied onto said base cosmetic product.... Agent: Lucas & Mercanti, LLP

20080063677 - Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations: The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and... Agent: Hoffmann & Baron, LLP

20080063678 - Novel 2-cyano-3(halo)alkoxy-benzenesulfonamide compounds for combating animal pests: Moreover, the present invention relates to the use of compounds I and/or their salts for combating animal pests; agricultural compositions comprising such an amount of at least one compound of the general formula I and/or at least one agriculturally useful salt of I and at least one inert liquid and/or... Agent: Hutchison Law Group PLLC

20080063679 - Nanocomposites with residual biocidal and biostatic properties: We disclose novel classes of alloy nanocompositions that have superior decontaminant properties which are derived from their superior immediate and residual biocidal properties. By decontaminant properties it is understood that the preferred compositions are antiseptics, disinfectants, sanitizers, and/or sterilizers. By biocidal properties it is understood that the preferred compositions are... Agent: Reyad Sawfta Quartek Corp.

20080063680 - Dried collagenous biomaterial medical device prepared from a urinary tissue source: The invention involves a submucosa tissue that has the capability of being shape formed or shape configured. The submucosa involves a purified form of submucosa tissue. Optionally, the submucosa can be packaged in such a manner to permit sterility or maintain sterility of the submucosa.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080063681 - Therapeutic bone replacement material: A biodegradable bone replacement material for the treatment of bone defects and delivery of antibiotic compounds, particularly for treating bone infections, comprising calcium sulfate hemihydrate, calcium sulfate dihydrate, an antibiotic mixture comprising a tetracycline compound and an ansamycin compound. Preferably, the ratio of calcium sulfate hemihydrate to calcium sulfate dihydrate... Agent: Harness, Dickey & Pierce, P.L.C

20080063684 - Formable and settable polymer bone composite and methods of production thereof: A composite osteoimplant. The osteoimplant includes a polymer and bone-derived particles. The composite is adapted and constructed to be formable during or immediately prior to implantation and to be set after final surgical placement.... Agent: Choate, Hall & Stewart LLP

20080063682 - Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans: Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent.... Agent: Graybeal, Jackson, Haley LLP

20080063683 - Processes for treating coral and coating an object: The present invention generally relates to an improved process for the hydrothermal conversion of coral into hydroxyapatite, a process for coating an object with hydroxyapatite, a process for coating an object with a divalent metal phosphate and uses of objects prepared by these processes. Following the processes according to the... Agent: Nixon & Vanderhye, PC

20080063685 - Degradable polymeric implantable medical devices with continuous phase and discrete phase: An implantable medical device is disclosed comprising: a structural element, wherein the structural element includes: a continuous phase comprising a first polymer of LPLG; a discrete phase within the continuous phase, wherein the discrete phase comprises a second polymer including rapidly eroding elastic discrete phase segments. The second polymer further... Agent: Squire, Sanders & Dempsey LLP

20080063686 - Resorbable thin membranes: Resorbable lactide polymer thin membranes are disclosed. The thin membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between... Agent: Kenton R. Mullins Stout, Uxa, Buyan & Mullins, LLP

20080063687 - Injectable sustained release delivery devices: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080063688 - Biomedical devices with antimicrobial coatings: Biomedical devices with antimicrobial coatings are provided. One or more surfaces of the device are coated with a cationic peptide, cationic proteins, or mixtures thereof to impart antimicrobial properties to the surface.... Agent: Philip S. Johnson Johnson & Johnson

20080063689 - Dietary supplements containing anthocyanins and methods for using same to enhance creatine absorption and vasodilation: A problem with optimizing the effects of creatine has been the need to utilize large amounts of high glycemic carbohydrates to spike insulin in order to augment the flow of creatine (and other nutrients) into the muscle cell. Based upon current research, an insulin response strong enough to ensure absorption... Agent: Reine H. Glanz Suite 6c

20080063690 - Nut skin products: The invention relates to products, including foods such as confectionary and pet foods, comprising nut skins. Exemplary nut skins are peanut and almond skins. The products may also contain cocoa polyphenol and/or L-arginine, and are useful for inducing vasodilation.... Agent: Nada Jain, P.C.

20080063691 - Fatty acid desaturases from primula: The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes... Agent: Sonnenschein Nath & Rosenthal LLP

20080063692 - Isomaltooligosaccharides to inhibit avian pathogenic intestinal bacteria: Isomaltooligosaccharides (IMOs) produced by Leuconostoc mesenteroides ATCC 13146 fermentation with a sucrose:maltose ratio of 2:1 have been discovered to be effective prebiotics in mixed cultures of microbial populations, including cultures from chicken ceca. Surprisingly in mixed microbial cultures this IMO composition proved as effective as FOS. Thus, these IMOs can... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20080063693 - Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation: The present invention provides antimicrobial coatings for coating substrate surfaces, particularly medical devices, for preventing bacterial adhesion and biofilm formation by inhibiting microbial growth and proliferation on the coating surface. The antimicrobial coatings are composed of a hydrogel and a bioactive agent including a substantially water-insoluble antimicrobial metallic material that... Agent: Kinney & Lange, P.A.

20080063694 - Material having antimicrobial activity when wet: An article is applied to the body of an animal (including humans) to provide both absorbency and antimicrobial activity. The article may comprise a water absorbent material; and a composition that reacts with water to produce molecular iodine. The composition provides a local concentration (in the water) of at least... Agent: Mark A. Litman & Associates, P.A.

20080063695 - Thin film dressing: Multi-layer articles are provided which are suitable for use as medical dressings. The articles include a hydrophilic layer, a hydrophobic layer, a delivery layer, and a release layer. In embodiments, the articles may also include adhesive tapes, stabilizer layers, and absorbent materials which may be included in an existing layer... Agent: Kendall (cdfs)

20080063696 - Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.... Agent: Morgan Lewis & Bockius LLP

20080063697 - Use of unactivated calcium exchanged zeolites in hemostatic devices and products: It is known that activated and partially activated zeolites are effective in hemostasis. However, the use of fully hydrated, unactivated zeolites has been ignored up to this point based upon a belief that it was necessary for such zeolites to concentrate certain components in the blood by removal of water.... Agent: Honeywell Intellectual Property Inc Patent Services

20080063698 - Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use: The invention relates to compositions and methods for making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically acceptable active agent carrier and a... Agent: Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq.

20080063699 - Method of administering cationic liposomes comprising an active drug: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.... Agent: Morgan Lewis & Bockius LLP

20080063700 - Support accumulating in injured part in vascular channel: The present invention provides a carrier that accumulates on a damaged tissue and that functions as a drug for controlling a platelet function, a drug delivery method using the carrier and a pharmaceutical composition comprising the carrier. The present invention also provides a carrier with a non-cationic surface, a drug... Agent: Dickstein Shapiro LLP

20080063701 - Vector: The present invention relates to a non-viral delivery vector comprising a liposome, wherein one or more lipids of the liposome are coupled, reversibly or irreversibly, to one or more polymers, and wherein the liposome comprises siRNA.... Agent: Fay Sharpe LLP

20080063702 - Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions: The present invention provides the use of an amphipathic weak base having defined characteristics for the preparation of a pharmaceutical formulation for the treatment or prevention of neurodegenerative conditions. Preferably, the amphipathic weak base is encapsulated in a liposome. The invention also provides pharmaceutical formulations and methods of use thereof... Agent: The Nath Law Group

20080063703 - Active drug delivery in the gastrointestinal tract: Apparatus (30) for drug administration is provided, including an ingestible capsule (32), which includes a drug (36), stored by the capsule (32), and an environmentally-sensitive mechanism (18), adapted to change a state thereof responsively to a disposition of the capsule (32) within a gastrointestinal (GI) tract (50) of a subject.... Agent: Ratnerprestia

20080063704 - Stable gabapentin compositions: The present invention provides a pharmaceutical composition of gabapentin wherein lactam level remains below 0.5% even after more than two years of storage at 25 to 30° C. and 60% relative humidity.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080063706 - Methods and medicaments for administration of ibuprofen: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.... Agent: Townsend And Townsend And Crew, LLP

20080063705 - Solid pharmaceutical composition comprising donepezil hydrochloride: The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.... Agent: Swanson & Bratschun, L.L.C.

20080063707 - Controlled release tablet formulations for the prevention of arrhythmias: Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080063708 - Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials: A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.... Agent: Pfizer Inc.

20080063709 - Pharmaceutical compositions having novel scoring patterns: The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, preferably doxepin.... Agent: Accu-break Technologies, Inc.

20080063710 - Rapidly disintegrating tablet and production method thereof: To provide a production method of a rapidly disintegrating tablet, the method that has versatility and, without a specialized device, can efficiently produce rapidly disintegrating tablets having a desired rapid disintegration property and sufficient strength. And also to provide such rapidly disintegrating tablets produced by the method, the tablets that... Agent: Birch Stewart Kolasch & Birch

20080063711 - Controlled release nisoldipine compositions: Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080063712 - Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level... Agent: Davidson, Davidson & Kappel, LLC

20080063713 - Particulate form of a pharmaceutical composition which is easy to swallow: The present invention relates to a pharmaceutical composition for direct oral administration which is very easy to swallow especially for young children, comprising at least one pharmaceutically active compound. The pharmaceutical composition is present in the form of one or more particles. The particles comprise a core containing the active... Agent: Smith Patent Consulting Consulting, LLC

20080063714 - Compositions for encapsulation and controlled release: The invention comprises compositions and methods useful for encapsulation and controlled release of guest molecules, such as drugs. Compositions of the present invention comprise a matrix comprising molecules that are non-covalently crosslinked by multi-valent cations, wherein the molecules that are non-covalently crosslinked are non-polymeric, have more than one carboxy functional... Agent: 3m Innovative Properties Company

20080063715 - Extracellular matrix to treat malignancy in mammals: The invention is compositions and methods for inhibiting growth of an abnormally proliferating cell in a mammal; methods include inhibiting growth of abnormally proliferating cells after tumor resection, and methods of recruiting stem cells to a site of malignancy; compositions include liquid or semi-solid extracellular matrix compositions having specified concentrations... Agent: Leigh Hunt Firestone

20080063716 - Method of formation of shape-retentive aggregates of gel particles and their uses: The present invention relates to a method of forming shape-retentive aggregates of gel particles in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a suspension of gel particles in a polar liquid at a... Agent: Foley & Lardner LLP

20080063718 - Delivery systems for delivering functional compounds to substrates and processes of using the same: Delivery systems for incorporating functional compounds into substrates for use in various consumer products are disclosed. Specifically, the delivery system includes a carrier component comprising an ultrasonically energized adsorbent and one or more functional compounds. The ultrasonically energized adsorbent can adsorb the desired functional compounds and bind the functional compounds... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20080063717 - Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same: The present invention relates to pharmaceutical compositions having an effect on the proliferation of NK cells, to a method for specifically stimulating the proliferation of NK cell and to the use of same in the manufacture of a drug for the antitumoral prevention, palliation, and therapy of e.g., melanoma, hepatocarcinoma... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080063722 - Composition of a spray-dried powder for pulmonary delivery of a long acting neuraminidase inhibitor (lani): The present invention is related to pharmaceutical formulations and methods of treating a subject afflicted with the influenza virus, the method includes administering to the respiratory tract of the patient particles that include more than about 5% to about 50% weight percent (wt %) of a neuraminidase inhibitor. The particles... Agent: Elmore Patent Law Group, PC

20080063720 - Delivery system: Therapeutic drug delivery and diagnostics systems comprise biologically active compounds associated with particulate carriers of less than 20 nm. These systems can be utilised for targeted modification of growth, development and functions, such as gene expression, protein synthesis, intracellular energy production and transport mechanisms in prokaryotic and eukaryotic organisms. The... Agent: Jacobson Holman PLLC

20080063723 - Isothiazolin-3-one-containing antimicrobial composition: The present invention relates to an antimicrobial composition that includes at least one isothiazolin-3-one and at least one alkyl amine containing a primary, secondary or tertiary amine functional group and having an average chain length of between eight and eighteen carbons per molecule of the alkyl amine.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080063721 - Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080063719 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions comprising the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the present invention relates to dry powder compositions which exhibit improved stability over time, and methods for producing the same.... Agent: Davidson, Davidson & Kappel, LLC

20080063724 - Methods and compostions for treating proliferative diseases: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations... Agent: Morrison & Foerster LLP

20080063725 - Prolonged-release multimicroparticulate oral pharmaceutical form: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.... Agent: Patton Boggs LLP

20080063726 - Fenofibrate compositions: The invention provides fenofibrate compositions comprising granulates, where the granulates comprise micronized fenofibrate.... Agent: Venable LLP

20080063727 - Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.... Agent: Sughrue Mion, PLLC

20080063728 - Antimicrobial glass surfaces of glass powders: s

20080063729 - Dressing and antiseptic agent containing silver: The invention relates to a process for destroying or inhibiting growth of micro-organisms on living tissues, comprising applying an antiseptic agent comprising a dispersion of a transition metal in an imogolite and/or allophane-like matrix to living tissue.... Agent: Patent Legal Staff Eastman Kodak Company

20080063730 - Methods for prophylactic and therapeutic nutritional supplementation: The present invention relates to methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising vitamin A, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, iron,... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080063731 - Mineral infused polyol and method to improve metabolism of individual: A process is provided to improve the insulin sensitivity and glucose tolerance of an individual's metabolism. The process includes providing at a first location at least one polyol in an aqueous solution. A minor effective amount of a water soluble mineral composition comprising chromium picolinate is admixed with the aqueous... Agent: Tod R Nissle

20080063732 - Method of increasing the efficacy of neurotoxin: The present invention provides a method of increasing the efficacy of treating a muscle or sweat gland hyperactivity condition in a human or mammal with a neurotoxin. The method includes adding a quantity of either a diffusion-limiting agent or an anti-metabolic agent to the neurotoxin. Adding the agent to the... Agent: Lumen Patent Firm, Inc.

20080063733 - Product of vegetal origin comprising proanthocyanidines and its preparation process: A product of vegetal origin with a high percentage of proanthocyanidines with molecular weight of greater than 6000 daltons, a very high percentage of which proanthocyanidines have a molecular weight of greater than 30000 daltons, produces a great hypercholesterolaernic effect at acceptable doses for human consumption and little astringent and... Agent: Berenbaum, Weinshienk & Eason, P.c

20080063734 - Medical herb composition for the alleviation of cardiopulmonary ailments or the improvement of cardiopulmonary function in a mammal: A medical herb composition for the alleviation of cardiopulmonary ailments or the improvement of cardiopulmonary function in a mammal is disclosed. The medical herb composition comprises: Schisandra extract; Ginseng extract; Radix ophiopogonis extract; and Saliva miltiorrhiza extract. The medical herb composition comprising the extracts above is proved to be efficient... Agent: Bacon & Thomas, PLLC

20080063735 - Antimicrobial and/or antiviral composition and to methods for preparing and administering same: The present invention provides for a therapeutic aromatherapy spray composition suitable for administration to a surface. The therapeutic aromatherapy spray composition includes an effective amount of an essential oil portion capable of enhancing the mood of a human and a volatile liquid carrier that readily evaporates after dispersal onto the... Agent: Summa, Allan & Additon, P.A.

20080063736 - Composition having effect of moxibustion and press pellet using the same: Disclosed herein is a composition with moxibustion effects comprising 20-40% by weight of an artemisia extract, 0-20% by weight of an auxiliary herbal material, 0-20% by weight of a resin and 30-60% by weight of a far-infrared radiating powder. Further disclosed is a method for preparing the composition, a press... Agent: Daniel B. Schein, Ph.d., Esq., Inc.

20080063737 - Cosmetic-dermatological topical preparation and manufacturing process thereof: A cosmetic-dermatological topical preparation useful in the treatment of cosmetic-dermatological conditions such as striae, commonly known as stretch marks, acne, age spots, burn marks and in general in a variety of skin marks or imperfections. The core of the effectiveness of the preparation lies not only in the specific ingredients... Agent: Maria Rosaria Brunese

20080056990 - Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase: Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed... Agent: Martin D. Moynihan Prtsi, Inc.

20080056992 - Biological marker for inflammation: Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080057002 - Non-aqueous compositions containing urea and allantoin and methods for preparing same: A method for enhancing solubility of allantoin in a non-aqueous pharmaceutically acceptable alcohol carrier using a solubilization enhancer is described. Non-aqueous compositions containing the solubilized allantoin at the FDA-approved levels of 0.5% to 2% by weight are able to be obtained by using urea or urea derivatives as the solubilization... Agent: Jerry Zhang

20080057006 - P. gingivalis vaccine: A vaccine composition is provided which comprises a rag nucleic acid sequence for the prevention and/or treatment of infection by P. gingivalis. Uses of such nucleic acid sequences, proteins coded for by such sequences and antibodies raised against such proteins in medicine are also provided. Kits for the detection of... Agent: Xiaoju Shi

20080057008 - Metal oxide dispersion: A dispersion contains particles of metal oxide having a median volume particle diameter in the range from 24 to 42 nm which are dispersed in a medium which includes a mixture of at least one polar material having an interfacial tension of less than 30 mNm−1 and at least one... Agent: Jones Day

20080057010 - Method for skin care: The present invention provides a method for skin care comprising administering an the water insoluble fraction of Astragalus membranaceus, or astragaloside compounds to a subject in need thereof at an effective amount for improving skin texture, reducing wrinkles, UV protection, and anti-aging effect.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080057009 - Talc-based sand removing sun care powder.: A talc-based, scented, colored, deodorizing, moisture absorbing, soothing, antioxidant sun care powder composition used to remove sand particles from one's skin. The method of using said composition involves shaking the powder either into one's hand or onto the affected area of one's body and wiping away sand, moisture, and odor... Agent: Michael Brett Grunhaus

20080057013 - Lip gloss compositions with enhanced shine: Disclosed are lip gloss compositions containing a non-polyurethane oil-absorbent particulate material, a film forming copolymer, an oil having a refractive index of at least 1.40, and a wax.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080057018 - Compositions and methods of use thereof for the removal of ticks from epidermal tissue: Provided are compositions and an article for manufacture with an associated writing comprising the composition for the removal of ticks embedded in the skin or tissues of a human or animal host. Moreover a method is provided for removal of ticks embedded in the skin or tissues of a human... Agent: Buchanan, Ingersoll & Rooney LLP

20080057022 - Ophthalmic pharmaceutical compositions and uses thereof: A composition for providing relief to a discomfort of an eye comprises a pharmaceutically acceptable carrier and a material that allows the composition to remain in an ocular environment for an extended period of time. The composition can further comprise an active ingredient selected from the group consisting of anti-allergic... Agent: Bausch & Lomb Incorporated

20080057023 - Oxygenated ophthalmic composition: The present invention relates to oxygenated ophthalmic topical compositions and methods of administering oxygenated ophthalmic topical compositions. The present invention also encompasses methods for making and administering the oxygenated ophthalmic topical compositions for use in treating or ameliorating pathologic conditions, complications, diseases and symptoms related to hypoxia of the anterior... Agent: Darby & Darby P.C.

20080057024 - Stimuli responsive polyester amide particles: A composition including a solution suitable for introduction into a blood vessel comprising particles including a treatment agent and a tunable stimuli-responsive polymer. A method including introducing a delivery device into a blood vessel; and introducing a solution into the blood vessel, the solution including particles comprising a treatment agent... Agent: Blakely Sokoloff Taylor & Zafman

20080057026 - Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses threof: Biomedical uses of amphiphilic macromolecules include the use of such macromolecules in the form of nanoparticle formulations for the sequestration and/or removal of LDL, and for the treatment and prevention of atherosclerosis and atherosclerotic development. The invention also provides the use of amphiphilic macromolecule encapsulates for treating diseases including cancer... Agent: Viksnins Harris & Padys Pllp

20080057027 - Methods and devices to regulate stem cell homing: A device for altering the expression or activation of adhesion molecules on cells including endothelial cells, as well as methods for altering the expression or activation of adhesion molecules on cells including endothelial cells, are provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080057028 - Vegf-c or vegf-d materials and methods for stimulation of neural stem cells: The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells, neuronal and neuronal precursor cells, oligodendrocytes and oligodendrocyte precursor cells and materials and methods for administering said cells to inhibit neuropathology.... Agent: Marshall, Gerstein & Borun LLP

20080057030 - Methods of treating idiopathic pulmonary fibrosis: The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.... Agent: Li-hsien(lily) Rin-laures Marshall, Gerstein & Borun LLP

20080057033 - Neural stem cells and methods of generating and utilizing same: Methods of generating neural stem cells and neural stem cell culture generated by such methods are provided.... Agent: Martin D Moynihan Prtsi Inc

20080057036 - Modified oncolytic viruses: An isolated selected Picornavirus capable of lytically infecting or killing a cell substantially in the absence of intercellular adhesion molecule-1 (ICAM-1).... Agent: Dla Piper US LLP

20080057039 - Diagnostic and therapeutic treatments related to mitochondrial disorders: Abstract: The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk... Agent: Robert Berliner Fulbright & Jaworski

20080057052 - Compositions and methods for treating cancer: An improved more comprehensive understanding of tumors is disclosed including a precise molecular etiology leading to tumor cell growth. The disclosed molecular etiology explains the lack of control of tumor cell growth as well as the activation of a variety of phenotypic and pathological molecular mechanisms that are the natural... Agent: Bell, Boyd & Lloyd, LLP

20080056987 - Quinoline derivatives, their preparation, their use, and medicaments comprising them:

20080056988 - [18f]-furanosylpurine derivatives and uses thereof: 2′-Deoxy-2′-[18F]-labeled and 3′-deoxy-3′-[18F]-labeled purine nucleoside analogs such as [18F]-FAA and [18F]-FXA have been found to have desirable properties for use as imaging agents. The analogs are particularly useful for in vivo imaging of biological material including organ tissues (e.g., heart, liver, brain and kidneys) and tumors. Methods for the preparation... Agent: Hogan & Hartson L.L.P.

20080056989 - Novel dyes for organ function monitoring: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Thompson Hine L.L.P. Intellectual Property Group

20080056991 - Piperazinyl and diazapanyl benzamides and benzthioamides: Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20080056994 - Assays for diagnosing and evaluating treatment options for fabry disease: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.... Agent: Baker Botts L.L.P.

20080056993 - Compositions, methods and kits using adenosine and inosine in combination for diagnosis and treatment: The present disclosure relates to compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment.... Agent: Dechert LLP

20080056996 - Photodynamic therapy for the treatment of hair loss: Photodynamic therapy (PDT) is used to stimulate and/or restore hair growth in areas of hair loss. Methods and compositions relating to PDT treatment for alopecia are disclosed. In light of PDT use to remove unwanted hair by inactivating or destroying hair follicles or destroying the tissue feeding the hair follicles,... Agent: Morrison & Foerster LLP

20080056995 - System and methods for measuring a skin protection factor: o

20080057001 - Contrast agents for imaging: Contrast agents and methods for making them are presented that use Fe nanoparticles that produce higher clarity and particularity in MRI imaging. Various alloys and core compounds are presented that may be used to produce such higher clarity MRI images.... Agent: Sherr & Nourse, PLLC

20080056997 - Antibodies against tenascin-c: Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.... Agent: Dann, Dorfman, Herrell & Skillman

20080056998 - Composition and processes for crossing the blood-brain barrier with polypeptides for in vivo neuroimaging: According to an exemplary embodiment of the present invention, a versatile delivery module based on a myristoylated polyarginine backbone can be provided to cross a blood-brain barrier (“BBB”). An incorporation of a fatty acid group can be achieved using a Schotten-Bauman reaction with quantitative yield, and a peptide can be... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080056999 - Imaging agents for functional imaging of lymphatic structures: Novel imaging agents targeted to a lymph vascular cell receptor and a hyaluranon cell receptor are disclosed. The disclosed imaging agents incorporate biological molecules such as hyaluronic acid which bind to the receptors. Lymph vascular cell receptor expression may be related to the beginnings of tumor formation. As such, embodiments... Agent: Conley Rose, P.C. David A. Rose

20080057000 - Dental compositions having anti-stokes up converters and methods of use: A dental composition can include at least one polymerizable resin and at least one anti-stokes up converter. Alternatively, a two-part composition can include at least one dental composition configured for placement onto a person's tooth, and at least one anti-stokes up converter to be combined with the at least one... Agent: Workman Nydegger

20080057004 - Albumin-insulin fusion proteins: Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin... Agent: Foley And Lardner LLP Suite 500

20080057003 - Powder inhaler formulations: The present invention relates to new methods for the surface modification of powders. Furthermore the present invention relates to new, improved pharmaceutical dosage forms obtainable by the new methods for surface modification of drugs according to the invention and to the use of these pharmaceutical dosage forms within dry powder... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080057005 - Hydrogels for the controlled release of bioactive materials: The present invention relates to the formation of hydrogels based on guanosine hydrazide derivatives in the presence of cations. The hydrogels can be used as a carrier/delivery system for biologically active substances such as flavors, fragrances, insect attractants or repellents, bactericides, fungicides, pharmaceuticals or agrochemicals.... Agent: Winston & Strawn LLP Patent Department

20080057007 - Oral hygiene products containing ascorbic acid and method of using the same: The present invention is directed to dental compositions, including dentifrices, containing ascorbic acid for removing and inhibiting dental biofilms which form plaque and tartar, and also for treating and preventing gingivitis and periodontitis. The ascorbic acid composition can contain may additional ingredients, including an enamel-strengthening component, and be used in... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080057011 - Composition structured with a polymer containing a heteroatom and an organogelator: A physiologically acceptable composition, in particular a cosmetic composition, comprising at least one liquid fatty phase which comprises (i) at least one structuring polymer having a polymer skeleton which comprises at least one hydrocarbon-based repeating unit comprising at least one hetero atom; and (ii) at least one organogelator.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080057012 - Self-tanning product having slimming, firming and toning properties associated therewith: A sunless or self-tanning composition having slimming, firming and toning properties associated therewith. The composition is an emulsion containing safe effective amounts of sunless tanning agents and slimming, firming and toning constituents. A method for preparing such composition is disclosed.... Agent: Dunlap Codding & Rogers, P.C.

20080057014 - Personal care composition comprising hydrophobic gel: Disclosed is a polyol-in-silicone emulsion consisting essentially of: (i) an alkyl dimethicone copolyol having an HLB of from about 4 to about 6, and a molecular weight of from about 10,000 to about 20,000, wherein the alkyl group is made of about 10 to about 22 carbons; and (ii) a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080057016 - Conditioning shampoo compositions containing select cationic conditioning polymers: Disclosed are aqueous conditioning shampoo compositions which comprise an anionic detersive surfactant component; from about 0.025% to about 5% by weight of an water soluble or dispersible, cationic, non crosslinked, deposition or conditioning polymer; the conditioning shampoo may additionally comprise dispersed, liquid, droplets of a water insoluble, hair conditioning agent... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080057017 - Pre-shave compositions and methods of using same: Preshave compositions and methods of using such compositions are disclosed. The present preshave compositions include at least about 50% by weight of a polyalkylene glycol component, preferably including at least two portions of different molecular weights, and an additional component in an amount effective to benefit the area of the... Agent: Stout, Uxa, Buyan & Mullins LLP

20080057015 - Hair care compositions, methods, and articles of commerce that can help maintain a longer lasting hair style appearance: Hair care compositions, methods, and articles of commerce that can help maintain a longer lasting hair style appearance, including coloring and grooming. Such compositions can be applied to any areas where maintenance of longer lasting hair style appearance is desired, such as the scalp, neck, and/or beard. The present invention... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080057019 - Compositions and methods for imparting odor resistance and articles thereof: Described herein are compositions and methods for imparting odor resistance to an article. Also described herein are articles treated with the compositions and methods described herein.... Agent: Gardner Groff Greenwald & Villanueva. PC

20080057020 - Pasty composition for sanitary ware: The present invention relates to a cleaning and/or deodorizing pasty composition for sanitary ware, wherein the composition comprises a detersive surfactant and further comprises dispersed water soluble particles capable of absorbing water.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080057021 - Rinse-off personal care compositions comprising cationic perfume polumeric particles: Rinse-off personal care compositions comprising a perfume polymeric particle, which is useful as a delivery system for a perfume raw material (“PRM”), methods for making such personal care compositions and methods of treating substrates, such as skin and/or hair with such personal care compositions are provided.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080057025 - Method for promoting bone formation: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.... Agent: Attention: Christopher M. Beck, Phd Legal Department

20080057029 - Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine: This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the... Agent: Bozicevic, Field & Francis LLP

20080057031 - Antiviral phosphinate compounds: The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20080057032 - Combination therapy (temozolomide and alpha-ifn) for advanced cancer: There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and alpha interferon are administered in combination in amounts sufficient to achieve a clinical response.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080057034 - Attenuated fnr deficient enterobacteria: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject... Agent: Myers Bigel Sibley & Sajovec

20080057035 - Methods of treating various cancers using melanoma differentiation associated protein-7: This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This... Agent: Baker Botts L.L.P.

20080057043 - Monocyte cell: A human monocyte cell characterised by the expression of the following markers: Tie2, CD16 and CD14.... Agent: Steptoe & Johnson LLP

20080057045 - Compositions and methods for inhibiting pathogenic growth: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an... Agent: Houston Office Of Novak Druce And Quigg LLP

20080057046 - Lactic acid producing bacteria for use as probiotic organisms in the human vagina: The present invention discloses novel isolated strains of lactic acid producing bacteria of the genera Lactobacillus and Pediococcus, and a method for isolation of such bacterial strains, having the ability to colonise and become established in a human vagina, even during menstrual discharge. Furthermore, a composition comprising said bacterial strains... Agent: Birch Stewart Kolasch & Birch

20080057044 - Lactobacillus plantarum with body-fat reducing activity and the foods containing them: The present invention relates to Lactobacillus strain with a body-fat reducing activity and provides Lactobacillus plantarum Strain PL62 KCCM-10655P. The strain of the invention can be directly used as body-fat reducing functional foods, or can be used as additives of body-fat reducing functional foods or a ferment starter strain of... Agent: Birch Stewart Kolasch & Birch

20080057047 - Use of bacillus amyloliquefaciens pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases: Bacteria of the sp. Bacillus that produce a lipopeptide are found to be effective in the treatment and prophylaxis of gastro-intestinal disease when administered as a probiotic. In particular, a strain of Bacillus bacteria identified as PB6 is useful for the treatment of Antibiotic Associated Diarrhea (AAD) or the more... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Financial Center

20080057038 - Targeted drug-carrying bacteriophages: The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of... Agent: Winston & Strawn LLP Patent Department

20080057037 - Treatment of neoplasms with viruses: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to... Agent: Nixon & Vanderhye, PC

20080057040 - Cell preservation method: The present invention provides a method for freezing a stem cell or a cell derived therefrom, the method including the steps of providing a cell suspension, performing ice nucleation on the cell suspension, and lowering the temperature of the ice nucleated cell suspension to a temperature sufficiently low to allow... Agent: Scully Scott Murphy & Presser, PC

20080057041 - Derivation of embryonic stem cells and embryo-derived cells: This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080057042 - Method of providing readily available cellular material derived from cord blood, and a composition thereof: The present invention is directed to the TVEMF-expansion of mammalian cord blood stem cells in a rotating TVEMF-bioreactor, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions. Various benefits and advantages to the compositions of the present invention are... Agent: Ladas & Parry LLP

20080057048 - Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080057049 - Cationic latex as a carrier for bioactive ingredients and methods for making and using the same: This invention relates to latex compositions that incorporate at least one bioactive component such as an antibacterial or antifungal agent, and methods for making and using such latex compositions. The latex compositions disclosed herein can be prepared by the emulsion polymerization of the latex component monomers in the presence of... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080057050 - Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke: The invention refers to the use of non-neurotoxic plasminogen activating factors, e.g., from Desmodus rotundus (DSPA) or genetically modified plasminogen activating factors, for example of human origin, for the therapeutic treatment of stroke in mammals.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080057051 - Method for fostering bone formation and preservation: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any... Agent: Ostrolenk Faber Gerb & Soffen

20080057053 - Bispecific antibodies and agents to enhance stem cell homing: A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and/or agents... Agent: Schwegman, Lundberg & Woessner, P.A.

20080057056 - Fc variants with increased affinity for fcyriic: The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20080057054 - Modulation of phagocytosis in neurons: The invention relates to the field of phagocytosis and more particularly to the field of neurons and neuron diseases. In particular the invention relates to the use of molecules capable of modulating the phagocytosis in neurons, more particularly to molecules modulating the activity of telencephalin.... Agent: Trask Britt

20080057055 - Old-35 as an inflammatory agent: The present invention relates to the discovery that OLD-35, at least in part through the generation of reactive oxygen species, induces a number of inflammatory cytokines and promotes nuclear translocation and binding of the transcriptional activator NF-κB. Accordingly, the present invention provides for assay systems (which either utilize the old-35... Agent: Baker Botts L.L.P.

20080057057 - Anti-lipid rafts antibodies: The present invention relates to the discovery of antibodies able to modulate (prevent or favour) conversion of PrPc to PrPSc and to their antigens. Depending on the nature of the antibodies (antagonistic or agonistic), their respective antigens are either conversion factors or inhibitors of prion replication.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080057060 - Method and system to remove cytokine inhibitor in patients: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080057059 - Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein S inhibitor, and the use thereof for treating bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department

20080057058 - Uses of il-23 agonists and antagonists; related reagents: Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.... Agent: Dnax Research Inc. Legal Department

20080057061 - Method of treating diseases and disorders: We have discovered that targeting carbohydrates on cell, or viral particle surfaces, such as using antibodies against such carbohydrates also called glycans provide a new tool to treat diseases and disorders, such as viral diseases and malignant tumors. Therefore, the present invention provides methods for treating individuals affected with diseases... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20080057062 - Agent for inducing senescence and apoptosis of cancer cell: An object of the present invention is to further examine the functions of the above CARF in detail so as to develop a novel drug through elucidation of such functions. The present invention provides an anticancer agent which comprises an agent for suppressing CARF expression or an agent for inactivating... Agent: Greenblum & Bernstein, P.L.C

20080057063 - Antibodies directed to alphavbeta6 and uses thereof: Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080057064 - Erbb3 based methods and compositions for treating neoplasms: The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying neoplasm in a mammal using an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or a functional fragment thereof. The present... Agent: Jones Day

20080057066 - Methods and compositions for targeting relt: Anti-RELT monoclonal antibodies, and methods for using the antibodies, are provided. Methods of using RELT polypeptides and nucleic acids in modulating immune cell development and in modulating cytokine production are also provided.... Agent: Genentech, Inc.

20080057065 - Phep, an amino acid permease of staphylococcus aureus: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.... Agent: Speckman Law Group PLLC

20080057067 - Polypeptides and polynucleotides \"basb040\" from neisseria meningitidis and vaccine comprising said polypeptides and polynucleotides: The invention provides BASB040 polypeptides and polynucleotides from Neisseria meningitidis encoding BASB040 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylacetic and therapeutic uses.... Agent: Ratner & Prestia- Sb Division

20080057069 - Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue: This invention provides a method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising administering to the subject an agent that inhibits interaction between Stromal-Derived Factor-1 and CXCR-4.... Agent: John P. White Cooper & Dunham LLP

20080057068 - Sarms and method of use thereof: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and/or disorders, bone-related diseases and/or disorders, diabetes, cardiovascular disease, renal disease and others.... Agent: Pearl Cohen Zedek Latzer, LLP

20080057070 - Antagonist anti-cd40 monoclonal antibodies and methods for their use: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free... Agent: Alston & Bird LLP

20080057072 - Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders: Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous... Agent: Alcon

20080057071 - Use of hedgehog pathway inhibitors in small-cell lung cancer: Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in small-cell lung cancer (SCLQ cells, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating SCLC associated with elevated Hh pathway activity by reducing or inhibiting the... Agent: Dla Piper US LLP

20080057073 - Methods for the treatment of cellular proliferative disorders: The present invention relates to methods of identifying the susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling. The invention also pertains to methods using reovirus for the treatment of cellular proliferative disorders, and particularly cellular proliferative disorders wherein the proliferating cells exhibit constitutive MAPK phosphorylation, in mammals.... Agent: Fish & Richardson PC

20080057075 - Method of inducing neutralizing antibodies to human immunodeficiency virus: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.... Agent: Nixon & Vanderhye, PC

20080057074 - Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as... Agent: Sughrue-265550

20080057076 - Novel fibroblast growth factors: Novel nucleic acids, polypeptide sequences, and nucleic acid regulators thereof, have been identified which code for a fibroblast growth factor (FGF), preferably FGF-20 or FGF-23, a class of polypeptides involved in development, differentiation, and morphogenesis, e.g., in cell-cell signalling and cell proliferation. An FGF of the present invention, fragments thereof,... Agent: Bayer Health Care

20080057077 - Tumour-associated peptides binding to mhc-molecules: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080057078 - Chicken anemia virus vaccine from cell line: Provided is a chicken infectious anemia virus (CIAV) vaccine, comprising live CIAV passaged in MDCC-MSB-1 (MSB-1) cells, wherein the vaccine does not cause Marek's Disease. Also provided is a CIAV vaccine comprising a CIA virus having the sequence of SEQ ID NO: 1. A method of making a CIAV vaccine... Agent: Needle & Rosenberg, P.C.

20080057079 - Jc virus vaccine: The present invention includes compositions and methods for the development and use of a vaccine that includes one or more JC virus antigens in a carrier adapted to trigger a JC virus-specific immune response in the human intestinal tract.... Agent: Chalker Flores, LLP

20080057081 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... Agent: Johnathan Klein-evans

20080057080 - Influenza virus vaccine composition and methods of use: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080057082 - Vaccine: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080057083 - Polycationic carbohydrates as immunostimulants in vaccines: A polycationic carbohydrate such as chitosan, or a pharmaceutically acceptable derivative thereof, are used as immunostimulants. Vaccine compositions containing these polycationic carbohydrates, in particular in particles such as microparticles or liposomes are also described and claimed. Methods of treatment and the use of the polycationic carbohydrates as immunostimulants in the... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080057084 - Methods for selecting headache patients responsive to botulinum toxin therapy: A method for treating a headache by selecting a patient determined to be responsive to administration of a botulinum neurotoxin for treatment of a headache by determining that the patient has or has a propensity to have an imploding headache and/or an ocular headache pain and administering a botulinum toxin... Agent: Allergan, Inc.

20080057085 - Unique dna and polypeptide sequences based on the circumsporozoite protein of plasmodium vivax: Malaria in humans is caused by infection with Plasmodium species parasites including P. vivax. The biology and immunobilogy of P. vivax is distinct from that of P. falciparum. Provided are unique synthetic polypeptides and DNA molecules which encode them. Each of these molecules correspond to regions of the circumsporozoite protein... Agent: David S. Dolberg

20080057086 - Colon-targeted oral formulations of cytidine analogs: The present invention provides an oral formulation of a cytidine analog, including, 5-azacytidine, for delivery to the lower gastrointestinal tract, including, the large intestine; methods to treat diseases associated with abnormal cell proliferation by treatment with the oral formulations of the present invention; and methods to increase the bioavailability of... Agent: Swanson & Bratschun, L.L.C.

20080057087 - Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients: A multilayer preparation in the form of films of hydrophilic polymers for rapid release of substances present in the film layers into liquid surroundings is characterized in that adjacent layers differ from one another in that in each case one layer is soluble in a nonaqueous solvent in which the... Agent: Birch Stewart Kolasch & Birch

20080057088 - Anti-aging cream: A skin care composition is useful for augmenting cellular metabolism in skin cells and thereby enhancing the regulation of intracellular signaling. The composition comprises a primer for skin cell mitochondrial function, such as a Krebs cycle intermediate, a precursor of a Krebs cycle intermediate, salts or esters thereof, or combinations... Agent: Pearl Cohen Zedek Latzer, LLP

20080057089 - Light emitting personal lubricant technical field: Applicant's invention is a light emitting personal lubricant whose preferred embodiment comprises a combination of personal lubricant and luminescent particles such that when said particles are activated by a light source the personal lubricant takes on “glow in the dark” characteristics, or becomes light emitting.... Agent: Law Offices Of Gerald L. Robertson & Assoc.

20080057090 - Wrinkle masking film composition for skin: A film product composition that has a refractive index that matches the refractive index of the skin. The composition is made from polymers, polymers plus additives, including plasticizers, which have an average effective or actual refractive index of from 1.4 to 1.6. The refractive index of the composition matches the... Agent: Brett L. Nelson Eastman Chemical Company

20080057091 - Compositions with several hyaluronic acid fractions for cosmetic use: The present invention provides a moisturizing, cosmetic, or anti-wrinkle product comprising at least two hyaluronic acid fractions, or salts thereof, wherein a fraction has an average molecular weight in the range of 8,000-100,000 Da, and a fraction has an average molecular weight in the range of 500,000-1,100,000 Da.... Agent: Novozymes North America, Inc.

20080057092 - Dental whitening strips: A dental whitening strip which includes a carrier support having a whitening composition adhered to said carrier where the whitening composition comprises (a) dextrin; (b) a peroxide; (c) a non-toxic water soluble inorganic salt; (d) a acceptable hydroxy compound which is a plasticizer.... Agent: Hedman & Costigan P.C.

20080057093 - Lysm receptor-like kinases to improve plant defense response against fungal pathogens: Perception of chitin fragments (chitooligosaccharides) is an important first step in plant defense response against fungal pathogen. LysM receptor-like kinases (LysM RLKs) are instrumental in this perception process. LysM RLKs also play a role in activating transcription of chitin-responsive genes (CRGs) in plants. Mutations in the LysM kinase receptor genes... Agent: Lathrop & Gage Lc

20080057094 - Feeds and mineral supplements with insect repellant properties and methods of making and using: A feed or mineral supplement for animals, especially deer, contains effective amounts of sulfur and garlic to repel insects from the animals. By inducing the insect repellent into the animal via ingestion of the attractant, disease and stress in the animals as caused by the insects is reduced. A feed... Agent: Clark & Brody

20080057095 - Bone semi-permeable device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080057096 - Biocompatible stent: A biocompatible stent with a fluoride-containing hydrophilic water insoluble crosslinked resin layer. A therapeutic substance-containing layer may also be included. A method of making a biocompatible stent.... Agent: Crowell & Moring LLP Intellectual Property Group

20080057098 - Use of bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders: The present invention relates to new use of inhibitors of bcl-2/bcl-XI family of anti-apoptotic compounds for the treatment of post-angioplasty restenosis and in-stent restenosis. Small molecules of Bcl inhibitors are incorporated into a stent, typically by a fine polymeric coating over the metal, which would be placed during angioplasty of... Agent: Bruce E. Lilling Lilling & Lilling PLLC

20080057099 - Implant coatings having improved haemocompatibility: Implant coatings having improved haemocompatibility involve the use of alkaline chemically bonded ceramic systems based on Ca-aluminate as a thrombogenecity reducing coating material, especially intended for coating of devices used in the human or animal blood system.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080057100 - Implantable device for delivery of therapeutic agents: A percutaneously implantable device for the treatment of a cardiac condition or other disease is disclosed herein, the device capable of delivery and maintenance of a therapeutic scaffold. A therapeutic scaffold may comprise viable tissue to impart or restore normal cardiac function, or other therapeutic agent for the treatment of... Agent: Deanna J. Shirley

20080057097 - Medical devices having a coating for promoting endothelial cell adhesion: A medical device having a coating of cell adhesion polypeptides to enhance endothelial cell adhesion onto the medical device. The cell adhesion polypeptides may be any of the proteins of the extracellular matrix which are known to play a role in cell adhesion or derivative peptides such as RGD or... Agent: Kenyon & Kenyon LLP

20080057101 - Medical devices for controlled drug release: The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores... Agent: Workman Nydegger

20080057102 - Methods of manufacturing medical devices for controlled drug release: The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores... Agent: Workman Nydegger

20080057103 - Methods of using medical devices for controlled drug release: The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores... Agent: Workman Nydegger

20080057104 - Matrix metalloproteinase inhibitor delivering devices: Devices, systems and methods which employ inhibitors of particular matrix metalloproteinases (MMPs) are provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080057105 - Medical devices having nanostructured coating for macromolecule delivery: A medical device having a biodegradable coating comprising an inorganic material complexed to macromolecules. Biodegradation of the biodegradable coating releases nanoparticles of the inorganic material with macromolecules complexed to the released nanoparticles. The inorganic material may be applied directly onto the medical device as a nanostructured coating or be dispersed... Agent: Kenyon & Kenyon LLP

20080057106 - Low profile bioactive agent delivery device: Disclosed are implantable devices that are configured for implantation through tissue or membrane and into an implantation site comprising viscoelastic fluid or non-osseous tissue. In embodiments of the invention, the implantable devices comprise: (a) a nonlinear body member having a direction of extension, a longitudinal axis along the direction of... Agent: Kagan Binder, PLLC

20080057107 - Compositions for vaginal treatment: The invention provides mannose phosphate and salts thereof for increasing vaginal cell growth, vaginal cell maturation and vaginal moisture, as well as compositions, articles and methods for treating and preventing vaginal conditions characterized by poor vaginal cell growth, low vaginal cell differentiation and low vaginal moisture.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20080057110 - Compositions for alcoholic beverages and methods of producing thereof: Compositions and methods of producing an alcoholic beverage are provided that reduce and or prevent the after-effects of alcohol consumption and protect human organs during and after consumption of alcohol.... Agent: Shailaja Shirodkar

20080057109 - Bifidobacterium in the treatment of inflammatory disease: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may... Agent: Wolf Greenfield & Sacks, P.C.

20080057108 - Functional food and method for preparation thereof: A method is provided for preparing a functional food comprising the steps of: producing an aqueous solution of a malvaceous plant extract, adding fructan to the solution, and adjusting the solution to a determined temperature to obtain a solution containing fructose and/or oligofructose hydrolyzed from the fructan in the presence... Agent: Panitch Schwarze Belisario & Nadel LLP

20080057111 - Herbal composition for flu prevention and treatment: A herbal formulation for prevention and/or treatment of flu. The formulations comprise of plant or plant extract together with vitamins and conventional additives. The plant is isatis indigotica, or strobilanthes cusia or the mixture thereof The formulations are in the form of tablet, powder, capsule, liquid or gum. Preferably, the... Agent: Lixian Jiang

20080057112 - Oral products: An apparatus and method for forming a polymer film and/or oral dosage form having an active, content such as a vitamin, that is a considerable or relatively high proportion of the total dry weight percent without being unpleasant to taste, leaving a bitter after taste, having poor mouth feel and/or... Agent: Mcdermott Will & Emery LLP

20080057113 - Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof: A new anti-herpetic composition is proposed which comprises a virion preparation containing herpes simplex viruses of serotypes 1 and 2 inactivated by formalin or γ-irradiation; the composition further comprises a hi-tech immunomodulator Polyoxidonium, and also amino acids valine and lysine, as well as a combination consisting of at least two... Agent: Ladas & Parry

20080057114 - Sinker capsules: Sinker Capsules are gelatin capsules with two halves that are filled with a dense material, such as chocolate or other similiar material, in one half and medication in the other half. The bottonm part of the capsule is larger and is filled with medication. The medication is pressed into the... Agent: Gregor Dale Matthews

20080057115 - Capsule stable against mastication: The present invention relates to a soft capsule which is easily disintegrated in the stomach, wherein the contents thereof are not easily leaked at the time of mastication, which is obtained by providing a soft capsule comprising (2R)-2-propyloctanoic acid or a salt thereof with at least one property, preferably all... Agent: Sughrue Mion, PLLC

20080057116 - Emu oil and fruit composition: A composition is provided comprising emu oil and processed whole fruit. The composition is in a form for either topical application to human skin or for internal ingestion.... Agent: Mcgarry Bair PC

20080057117 - Pharmaceutical composition made up of cannibus extracts: A pharmacologically active composition which is suitable for use in palliative cancer therapy and as an agent having a muscle-relaxing and/or analgetic effect in neurological diseases. Said composition contains at least 80 wt. %, preferbly 90 wt. %, tetrahydrocannabinol (THC) an cannabidiol (CBD), in relation to the overall weight of... Agent: Hoffmann & Baron, LLP

20080057118 - Divalproex pharmaceutical compositions: Pharmaceutical compositions comprising a valproic acid drug compound, providing modified release of the drug.... Agent: Dr. Reddy's Laboratories, Inc.

20080057119 - Compositions and methods for treating middle-of-the night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080057120 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080057121 - Pharmaceutical composition and galenic form corresponding to rapid oral disintegration and method for production of said composition: The invention is based on a known method for the cold rolling of metallic rolled stock (4), which for plastic deformation enters a roll gap (3) formed between oppositely rotating rolls (1, 2) on a run-in side and leaves the roll gap on a run-out side, deformation heat that is... Agent: Alston & Bird LLP

20080057122 - Acetaminophen pharmaceutical compositions: Modified release dosage forms for daily oral dosing to a human patient for providing relief from pain are provided. The modified release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080057123 - Controlled release formulations: Controlled release oral dosage formulations containing one or more active agent, and methods of use thereof, are provided for the once-a-day treatment. The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. The core may contain one... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080057124 - Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties: n

20080057125 - Stable tablet dosage forms of proton pump inhibitors: This invention relates to a method of making oral formulations of practically water insoluble, or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a... Agent: Richard S. Roberts Roberts & Roberts, L.L.P., Attorneys At Law

20080057126 - Implant and process for its production: The present invention relates to an implant having a structured material component and having a protein matrix which has a pore structure. The structured material component is moreover at least partly anchored in the protein matrix. The implant also has on at least one its surfaces a protein membrane crosslinked... Agent: Harness, Dickey & Pierce, P.L.C

20080057127 - Functionalized non-phenolic amino acids and absorbable polymers therefrom: e

20080057128 - Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from: A drug delivery system that includes micelles formed from an amphiphilic copolymer that includes an A polymer block comprising a poly(alkylene oxide) and a B polymer block comprising a poly(hydroxyalkanoate), and a therapeutically effective amount of at least one therapeutic agent intimately contained within the micelles. In one preferred embodiment... Agent: Omeros Medical Systems, Inc.

20080057129 - Drug microparticles: Pharmaceutical compositions are described containing carrier particles bearing microparticles of a drug. The drug microparticles may be deposited on the carrier particles, for example, by sublimation. Preferred embodiments of these pharmaceutical compositions are suitable for administration by inhalation or injection. Methods for treating lung infection in patients with cystic fibrosis... Agent: Kenyon & Kenyon LLP

20080057130 - The surface treatment of nanoparticles to control interfacial properties and method of manufacture: A surface treated particle having a plurality of inorganic, metallic, semi-metallic, and/or metallic oxide particles and a star-graft copolymer with looped and/or linear polymeric structure on a star-graft copolymer, obtainable by a heterogeneous polymerization reaction in the particle surface proximity, encapsulating at least a portion of said particles and a... Agent: Wildman Harrold Allen & Dixon LLP

20080057131 - Method of modifying the release profile of sustained release compositions: The present invention relates to a method for the sustained release in vivo of a biologically active labile agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active labile agent incorporated therein, and a... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080057132 - \"got cha\": My invention “GOT CHA”, unique and different, invites the world to practice ecological awareness. It's the ultimate alternative embodiment eliminating toxicity at manufacturing levels of business. This product is world user friendly to all areas of industries that require exterminating insects whether they are crawling or flying, “GOT CHA” gets... Agent: Rafael Ralph Pagan

20080057133 - Preparation of aqueous clear solution dosage forms with bile acids: Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of... Agent: Baker Botts L.L.P.

20080057134 - Antifungal compositions and method: Efficacious antifungal compositions are prepared comprising a mixture of a traditional fungicide and an ion-exchange type antimicrobial agent.... Agent: Edward K. Welch Ii Ip&l Solution

20080057135 - Antimicrobial composition: An antimicrobial composition comprising metal particles that may be silver, copper, or gold together with a surfactant such as benzalkonium chloride in a liquid medium, which is preferably deionized water, that will not react with the other constituents of the antimicrobial composition. Preferably, the composition also comprises a source of... Agent: Thompson E. Fehr Suite 300

20080057136 - Disinfecting composition and methods of making and using same: The invention relates to antimicrobial compositions that can be used for disinfecting and can be applied in various aspects of the national economy, medicine, and laboratories of all types. The antimicrobial compositions comprise a chelating metal complex compound with a monodentate bidentate or polydentate ligand that exhibits affinity to hydrogen... Agent: Alston & Bird LLP

20080057137 - Treated wet process hardboard: A method of delivering and retaining zinc borate within a wet process hardboard is disclosed wherein process parameters are controlled and the borate is included in the overlay slush process of wet board processing.... Agent: Waddey & Patterson, P.C.

20080057138 - Restorative skin cream: This invention relates to topical creams which retard sun exposure damage to skin and restore skin health. More particularly, this invention pertains to a novel topical skin cream formulation which retards sun damage to skin and restores skin health comprising: (a) vitamin A retinyl at a concentration of 0.2% to... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080057139 - Skin-care water: The skin-care water, which is able to safely improve skin health conditions, such as dry skin, contains water from which polyvalent cations are removed and to which sodium ions are added, and may contain fragrant materials according to need. When the skin-care water is applied to skin, for example, by... Agent: Birch Stewart Kolasch & Birch

20080057140 - Use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency: The use of a lignan, which is a plant lignan, a metabolite thereof or a combination of both, for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency in an individual. Also disclosed is the use of a plant lignan capable of being a... Agent: James C. Lydon

20080057141 - Wake up on time dietary supplement and method of use: A time-released dietary supplement is disclosed. The dietary supplement is meant be taken upon going to bed in the evening. The active ingredients are released during the night so the person will wake up energized and refreshed.... Agent: Arthur M. Peslak, Esq. Mandel & Peslak, LLC

20080057142 - Compositions and methods for weight-loss and weight-loss maintenance in daytime and nighttime formulation: Compositions and methods for administering a diet supplement to humans are provided for the enhancement of weight loss, suppression of appetite, prevention of muscle protein catabolism, and providing antioxidants in either a daytime or nighttime formulation. Said diet supplement is comprised of at least a source of Catechins and at... Agent: Fitzpatrick Cella Harper & Scinto

20080057143 - Method of using composition comprising pomegranate extracts against influenza: The composition of one or more embodiments of the invention may be used to treat influenza viral infection, since the composition of the present invention has significant antiviral properties as demonstrated by the examples of this application. The composition of the present invention may also be used as a therapeutic... Agent: Dalina Law Group, P.C.

20080057144 - Wake up on time dietary supplement and method of use: A time-released dietary supplement is disclosed. The dietary supplement is meant be taken upon going to bed in the evening. The active ingredients are released during the night so the person will wake up energized and refreshed.... Agent: Arthur M. Peslak, Esq. Mandel & Peslak, LLC